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1 Introduction 
1.1 Proteins and Protein Synthesis 
Proteins are the most abundant biological macromolecule and exhibit enormous diversity of 
biological function ranging from enzymes, hormones, antibodies and transporters to building block 
and crucial components in organs such as muscle fibers, cytoskeleton or cell membrane. Proteins are 
the most important products of the genetic information pathway and are omnipresent in all life forms 
from viruses through single cell bacteria and up to the most complex multi-cellular organisms. They 
are of major interest in the biomedical, pharmaceutical and material science fields and study of 
proteins has always been of great interest to the scientific community [1].  
The study of proteins requires acquiring homogenous samples of defined composition, which 
are then used to determine the structure and function of the protein molecule. Once an understanding 
of the structure and function of individual protein molecules has been achieved, system-wide studies 
can be carried out to investigate how proteins interact with one another in the context of the proteome. 
Nowadays, preparation of proteins is achieved using two main approaches: biological methods to 
express proteins and total chemical synthesis of proteins.  
Current methods in molecular biology typically start with recombinant DNA expression, 
isolation and purification of a target protein. The structure of the target protein is then systematically 
varied by modern molecular biology techniques, and the effects of these changes are evaluated by a 
wide variety of methods aimed to gather new information such as binding affinities, post translation 
modification, or catalytic mechanisms. Proteins obtained via these methods are restricted to biological 
constrains, requiring special techniques to allow insertion of unnatural amino acids or modification 
[2]. Moreover, proteins go through post translational modifications in the cell and proteins of the same 
sequence can exhibit different modifications, making the protein sample heterogeneous and thus, study 
of the protein is highly restricted or in severe cases cannot be conducted at all. 
Chemical synthesis of proteins is advantageous over the biological methods as it allows total 
control over the protein sequence. Unnatural amino acids may be incorporated into the sequence 
selectively [3, 4], acting as probes for structure and function or for therapeutic purposes [5-7]. 
Moreover, any post translational modification can be introduced in a highly selective manner and in 
high yields. The previous years have seen development of several chemical ligation methods based on 
different chemical reactions such as click chemistry[8], oxime ligation[9], traceless Staudinger 
ligation[10, 11] or ketoacid-hydroxylamine (KAHA) ligation[12]. In the field of chemical synthesis of 
proteins, chemical ligation methods that rely on acyl-transfer and form the native peptide bond have 
been established as the paradigm for synthesis. 
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1.2 Protein Synthesis through Ligation Methods 
Solid phase peptide synthesis (SPPS), introduced in 1963 in the pioneering, ground breaking 
work of Merrifield [13] is still the method of choice for peptide synthesis. Despite major 
advancements and optimization in polymer supports, reagents, and automation of the method, SPPS is 
effective for the synthesis of polypeptide chains of only several dozen residues in length (depending 
on sequence) [14] due to the accumulation of resin-bound byproducts of incomplete coupling 
reactions. A number of works have been published presenting impressive synthesis of longer 
polypeptides using only sequential SPPS but the process is long, tedious, expensive and wasteful (due 
to multi-coupling steps, use of expensive activators and repetitive washing steps) with low isolated 
yields [15, 16]. To overcome this limitation, chemical ligation strategies have been developed for the 
total chemical synthesis of proteins [17]. Chemical ligation enables chemoselective conjugation of two 
peptide fragments to yield a single defined product. Due to the insolubility of long protected 
polypeptides, modern chemical ligation methods are performed in aqueous buffers using unprotected 
peptide fragments to give a larger polypeptide chain in a chemoselective manner (scheme 1.1A). In the 
early stages, the necessity for chemoselectivity resulted in ligation that formed unnatural bonds such as 
thioesters, thioether, oxime or thiazolidine [17-20] between the two peptide fragments (scheme 1.1B).  
 
 Scheme 1.1: A) Principle of chemical ligation of unprotected peptide fragments; B) non-native 
chemical ligation bonds. 1.004: thioester, 1.005: thioether, 1.006: oxime, 1.007: thiazolidine. 
 
The obvious drawback of the previously described ligation methods was the formation of an 
unnatural bond at the ligation site forming an unnatural mutation on the target which could limit its 
study for biological purposes. One of the early successful attempts to ligate two peptides yielding a 
native peptide bond was achieved by Kemp through prior thiol capture (scheme 1.2) [21]. The method 
relies on a rigid template based on dibenzofurane equipped with a thiol handle, attached to the peptide 
C-terminus (1.008). In the thiol capture step the disulfide intermediate 1.010 was formed, followed by 
O→N acyl transfer to yield the ligation product 1.011 which is reduced to the unmodified ligation 
product 1.012. The disadvantage is the slow reaction rate due to the medium ring size formed during 
the acyl transfer (12 member ring), and the poorly reactive C-terminal ester.  
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Scheme 1.2: Peptide synthesis by prior thiol capture. 
 
1.2.1 Native Chemical Ligation (NCL) 
In 1994, Kent and co-workers developed a new chemical ligation method titled "native 
chemical ligation" (NCL). Similar to an observation reported by Wieland [22], NCL enabled the 
formation of the native peptide bond at the ligation junction [23]. NCL involves a terminal C-
thioester and a N-terminal cysteinyl peptide. The mechanism comprises two steps: the thioester 
undergoes a reversible nucleophilic attack by the side chain thiol moiety of the N-terminal cysteine 
residue followed by spontaneous S→N acyl transfer through a five membered ring transition state, to 
form a native peptide bond (scheme 1.3). NCL is accomplished in presence of all functional groups 
present in proteins, in aqueous buffer at neutral pH and ambient temperature. Notably, the 
chemoselectivity is achieved even in the presence of additional cysteine residues as the formed 
thioester is reversible and unproductive. Seitz and co-workers have even shown that the presence of 
internal cysteine residues can accelerate the ligation rate [24, 25]. The first application of NCL was 
demonstrated by the full chemical synthesis of human interleukine-8 (IL-8), a 72-amino acid 
chemokine containing four Cys residues. [23]. 
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Scheme 1.3: Proposed Mechanism of NCL 
 
1.2.2 Extending Native Chemical Ligation 
The requirement of a cysteine residue at the ligation junction is an intrinsic limitation of NCL. 
Cysteine has low frequency in sequences which is estimated to be 1.3% [26]. Some proteins lack 
cysteine residues entirely, others do not have a cysteine residue at a synthetically beneficial position, 
and are therefore synthetically inaccessible by NCL. These limitations prompted the development of 
various methods that seek to extend the high efficiency of NCL. 
 
1.2.2.1 Conformationally Assisted Ligation 
The native chemical ligation of two peptides is achieved by the chemoselective reaction 
between a cysteine and a C

-thioester in denaturing conditions. An interesting approach titled 
“conformationally assisted ligation” [27] takes advantage of the native tertiary structure of a protein to 
bring the N-terminal and the C-thioester into close proximity. This allows for the direct attack of the 
amine on the thioester, eliminating the necessity of the transthioesterification step, and thus, making 
the cysteine residue at the N-terminal obsolete. Dawson and co-workers demonstrated the 
effectiveness of the method through the synthesis of Chymotrypsin Inhibitor 2 (CI2), a 64-amino acid 
protein lacking any cysteine residues making it inaccessible for synthesis via NCL. Early studies have 
demonstrated that the fragment CI(1-40) of CI2 binds a second fragment CI(41-64) to form a stable 
protein with a tertiary structure similar to that of the native protein. Initial studies using standard NCL 
were performed by altering the sequence of the peptide fragments. CI2(1-39)T39D-COSR and CI2(40-
64)M40C were synthesized and reacted under ligation condition to give the full CI2 within 8 hr. When 
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the modified peptide fragments were reacted under folding conditions, the ligation was complete in 
only 30 min. Ligation under folding conditions proceeded rapidly (30 min) even when the sterically 
hindered native threonine thioester CI2(1-39)-COSR was used. In comparison, under denaturizing 
conditions the same ligation required 48 hr to complete. Next, the native CI2(1-39) and CI2(40-64) 
were ligated. Expectedly, under denaturizing conditions no product formation was detected. When 
performed under folding conditions product was formed within 2 hr, demonstrating the importance of 
conformationally induced effective molarity for ligation. 
 
1.2.2.2 Thioalkylation and Ligation at Serine Junction 
 
Thioalkylation enables ligation to take place at methionine ligation junctions. In this approach 
homocysteine (HCY) is introduced into the sequence in place of methionine mimicking the cysteine 
function in NCL (1.017). Following ligation, the HCY is methylated to reform the native methionine 
1.019 in the sequence (scheme 1.4A) [28]. Methionine, however, is not common in sequences[26], 
reducing the applicability for protein synthesis. Moreover, if other cysteine residues are present, 
protection is needed to avoid alkylation of these residues. By using different alkylation reagents the 
method can also be used for forming unnatural amino acids at the ligation site such as thiolysine 1.020 
[29], thioglutamine 1.021 [29] or thioglutamate1.022 [30] (scheme 1.4B). The method could also be 
applied to introduce a serine residue at the ligation site by converting the cysteine upon reaction with 
cyanobromide to a depsipeptide that subsequently rearranges to form the serine-containing peptide 
[31] (scheme 1.4C).  
 
Scheme 1.4: Extending NCL using thioalkylation. A) Ligation at methionine; B) Thioderivatives of 
amino acids; C) Insertion of serine at ligation junction following methionine ligation. 
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1.2.2.3 Desulfurization 
 
Desulfurization is a frequently applied method used to convert cysteine to alananine after 
NCL. The concept has been extended to amino acids beyond alanine. For this purpose, an amino acid 
bearing a thiol handle at its  or carbon is required. Following ligation, desulfurization of the thiol 
handle converts the amino acid into the natural amino acid in the protein sequence (scheme 1.5A). 
 
 
Scheme 1.5: A) Principle of ligation-desulfurization B) Proposed mechanism for free-radical 
desulfurization. 
 
The method was introduced by Yan and Dawson, who used it to perform ligation at alanine 
[32]. During synthesis, alanine was replaced by a cysteine and NCL was performed. Following 
ligation, the cysteine residue was reduced using Raney Nickel to yield the native alanine residue. The 
application of this approach was demonstrated initially in the synthesis of the cyclic antibiotic 
microcin J25, the 56-amino acid streptococcal protein G B1 domain and a variant of the 110-amino 
acid ribonuclease, barnase [32]. The Raney nickel used to induce desulfurization proved incompatible 
with several functional groups, causing epimerization at threonine and reduction of thioethers and 
thioesters [33]. A new metal-free desulfurization method was later developed by Danishefsky and co-
workers based on a free-radical mechanism compatible with all native functional groups present on 
peptides (except other cysteine residues that must be protected to avoid desulfurization) [33]. The 
proposed mechanism involves a desulfurization reaction between sulfhydryl and trialkylphosphine 
derivatives. A thiyl radical reacts with phosphine, thereby generating an intermediate phosphoranyl 
radical. Subsequent  scission was envisioned to provide an alkyl radical, and rapid hydrogen 
abstraction from the parent thiol would furnish the product alkane, thereby serving to propagate the 
chain (scheme 1.5B). Since its introduction the method gained high popularity and numerous amino 
acids modified with a thiol handle were developed. Nowadays ligation-desulfurization has been 
demonstrated with phenylalanine [34, 35], valine [33, 36], threonine [37], lysine [38, 39], leucine [40, 
41], proline [42, 43], glutamine [44], glutamic acid [45] aspartic acid [46], tryptophan [4] and arginine 
[47] junctions. 
The method is not without its hindrances though. For one, excluding alanine, γ-proline and 
penicillamine (ligation at valine) which are commercially available, all of the modified amino acids 
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must be specifically synthesized. Another disadvantage is the necessity to temporarily protect other 
cysteine residues to avoid unwanted desulfurization. Thirdly, the ligation product needs to be purified 
before desulfurization can be performed, as the aryl thiol additives used as catalysts in ligations are 
excellent radical scavengers and therefore hinder the radical reaction. In recent years several groups 
have addressed these problems. The group of Brik has used a mercaptophenylacetic acid (MPAA) 
derivative containing a hydrazine moiety that was removed from the ligation buffer by passing the 
solution through an aldehyde resin. Desulfurization was sequentially performed without prior HPLC 
purification [48]. Payne and co-workers have recently demonstrated one-pot ligation-desulfurization 
using a new thiol additive- trifluoroethanethiol. This highly volatile thiol can be bubbled out of the 
ligation solution allowing desulfurization to occur [35, 49]. The same group has also published a very 
interesting study describing one-pot ligation-desulfurization of β-mercaptoaspartic acid without 
harming other cysteine residues in the sequence, thus avoiding extra protecting group chemistry 
manipulation and repetitive purification steps [46]. Desulfurization method is credited to some of the 
most ambitious accomplishments in the field of total chemical synthesis of proteins such as 
Danishefsky synthesis of the EPO protein [50] or synthesis of the 304 amino acid K64 linked 
tetraubiquitine employing δ-mercaptolysine to form the isopeptide bond (scheme 1.6) [51]. 
 
Scheme 1.6: Synthesis of tetraubiquitine isopeptide assisted by δ -mercaptolysine. 
 
1.2.2.4 Sugar-Assisted Ligation (SAL) and Side-Chain Assisted Ligation (SCAL) 
 
Sugar-assisted ligation (SAL) was developed by Brik and Wong to assist synthesis of 
glycoproteins (scheme 1.7A) [52]. Glycosylated proteins constitute 50% of all proteins in humans. 
They play central roles in biological processes as protein folding, secretion and cell targeting [53] 
making glycoproteins highly important targets for biological studies. In this method, a sugar modified 
with a thiol handle acts as the cysteine residue bringing the glycopeptide 1.033 amine functionality 
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and thioester peptide 1.013 to close proximity and assist the ligation. The thiol handle on ligation 
product 1.035 is removed using desulfurization methods, yielding the natural glycoprotein 1.036. SAL 
was successfully applied to the synthesis of N-, -O-, and -O- linked glycopeptides as well as for the 
total chemical synthesis of diptericin  glycoprotein [54-57]. 
Side-chain assisted ligation (SCAL) is a direct evolution of SAL, using a cyclohexane moiety 
in place of the sugar [58] designed not for the synthesis of proteins. Here, a thiol bearing cyclohexane 
or a cyclopentane auxiliary, is attached to the side-chain of Asp, Glu (1.037), Ser or Thr (1.040) 
residues through an ester bond (scheme 1.7B-C). In a similar fashion to SAL, the auxiliary facilitates 
the ligation step between two peptides forming the modified ligation products 1.038 or 1.041 
respectively. Following ligation, the auxiliary is hydrolyzed to furnish the native proteins 1.039 or 
1.042. 
The demonstration for the feasibility of side-chain assisted ligation was shown in the total 
synthesis of the HIV-1 Tat protein [59]. Tat is an 86-amino acids protein, which plays a crucial role in 
the life-cycle of the HIV virus. The protein contains seven cysteine residues, but all are located at the 
N-terminal of the protein thus, the synthesis through NCL cannot be accomplished. The synthesis took 
advantage of Ser 62 to enable SCAL between the C-terminal peptide and the middle fragment. NCL of 
the N-terminal peptide furnished the full-length HIV-1 Tat. Difficulties arose when attempts to remove 
the auxiliary failed. Apparently, once the full protein was achieved, the auxiliary was shielded from 
the medium and the hydrolysis could not proceed, leaving the auxiliary as an unnatural modification 
on the protein. 
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Scheme 1.7: A) Proposed mechanism for SAL; B) Side-chain assisted ligation at Asp and Glu 
residues; C) Side-chain assisted ligation at Ser and Thr residues. 
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Scheme 1.8: A) Auxiliary-Assisted NCL; B) Ensemble of available auxiliaries and ligation junctions 
available. 
 
1.2.2.5 Removable Auxiliaries 
Some of the earliest attempts to expand the scope of NCL used removable auxiliaries. 
Removable auxiliaries are small molecules bearing a thiol handle that are attached to a terminal amine 
of a peptide and mimic the cysteine function at the ligation site. Following ligation, the auxiliary is 
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removed to furnish the natural protein structure (scheme 1.8A). Demands for the auxiliary are an 
easily accessible synthesis, compatibility with standard solid phase peptide synthesis methods and a 
chemoselective removal once ligation is complete. 
The concept was first reported by Kent and co-workers using N-2-mercaptoethyl auxiliary 
1.047 and N-2-mercaptoethyloxy auxiliary 1.048  to promote ligation at a Gly-Gly junction [60]. The 
mercaptoethyloxy auxiliary 1.048 exhibited significant slower reaction rate in comparison to the 
mercaptoethyl auxiliary 1.047, presumably due to less favorable 6-membered ring size of the 
intermediate. However, the N-2-mercaptoethyl auxiliary 1.047 could not be removed and remained as 
an unnatural modification. The N-2-mercaptoethyloxy auxiliary 1.048 was removed by treatment 
with zinc dust under acidic conditions to give the native amide bond at the ligation site. Botti et al. 
introduced two acid-labile auxiliaries Nα-1-(4-methoxyphenyl)-2-mercaptoethyl 1.049b and Nα-1-(2,4-
dimethoxyphenyl)-2-mercaptoethyl 1.049c  [61, 62]. The utility of the auxiliary assisted ligation was 
demonstrated by Low et al. who used the Nα-1-(4-methoxyphenyl)-2-mercaptoethyl 1.049b to 
synthesize the 106 amino acid protein cytochrome b562 [63]. The auxiliary was later removed by 
treatment with anhydrous hydrofluoric acid to yield the full-length unmodified product. Offer et al. 
developed the 2-mercaptobenzyl auxiliary 1.049a. Although product formation at unhindered ligation 
junctions was established, the auxiliary was completely stable towards reduction or acidolysis [64]. An 
improved version of the benzyl auxiliaries was demonstrated first by the group of Aimoto who used 
the 4,5-dimethoxy-2-mercaptobenzyl auxiliary (Dmb) 1.049c. This auxiliary was removed post 
ligation by treatment with trifluoromethanesulfonic acid (TFMSA) [65]. Offer et al. presented an 
improved auxiliary by introducing the 4,5,6-trimethoxy-2-mercaptobenzyl auxiliary (Tmob) 1.050c 
[66]. By increasing the electron density of the aromatic ring in the auxiliary ligation efficiency as well 
as the acid lability were increased, thus achieving auxiliary removal using the milder triflouroacetic 
acid (TFA). The auxiliary assisted the synthesis of the 62-amino acid SH3 domain from -spectrin 
1.055 (scheme 1.9A) [67]. Aimoto [68], Dawson [69] and Diederichsen [70] all designed photolabile 
auxiliaries (1.051a, 1.051b, 1.050d) by substituting the benzene ring with a nitro group. These 
auxiliaries however suffer from slow rates and inability to ligate more demanding junctions. Muir used 
the 2-(4,5-dimethoxy-2-nitrophenyl)ethanethiolbenzyl auxiliary 1.051c to form an isopeptide bond 
between a truncated ubiquitine thioester 1.057 and the lysine side chain of a histone 1.058 to examine 
the biological effect ubiquitination on H2B has on the methylation of Lys79 at H3 (scheme 1.9B). 
Despite the sterically undemanding Gly-Gly ligation junction, the auxiliary-mediated ligation was 
extremely slow and was incomplete even after five days [5]. 
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Scheme 1.9: A) SH3 -spectrin synthesis assisted by Tmob auxiliary-mediated NCL; B) Isopeptide 
bond formation between ubiquitine and H2B assisted by the photolabile 2-(4,5-dimethoxy-2-
nitrophenyl)ethanethiolbenzyl auxiliary. 
 
The drawbacks of removable auxiliaries are the steric hindrance imposed by the auxiliaries 
limiting the use of this method to ligation sites containing at least one glycine. A second disadvantage 
of the acid labile auxiliaries is their incompatibility with acid labile post translational modifications 
such as glycosylation or sulfonation. Thirdly, under the acidic conditions needed to remove the 
auxiliaries, the S→N acyl shift reverses back to yield the thioester intermediate thus inhibiting the 
removal of the auxiliaries from ligation product. This problem can be solved by alkylation of the thiol 
handle prior to acid treatment to prevent the N→S acyl shift. However, it requires other cysteine 
residues in the sequence to be protected in order to avoid unwanted protein modification. 
1.2.3 Traceless Staudinger Ligation 
The reaction was introduced by Bertozzi[10] and Raines[11] and is based on the known 
Staudinger reaction[71], in which an azide reacts with a phosphine to form aminophosphorane. In the 
traceless Staudinger ligation the formation of the iminophosphorane 1.064 brings the nitrogen atom in 
close proximity to the thioester leading to an acyl shift and forming the amidophosphounium salt 
1.065. The complex is consequently hydrolyzed to yield ligation product 1.066 (Scheme 1.10). Since 
its introduction several aspects of the Staudinger traceless ligation have been improved: water soluble 
phosphinothiols have made it possible to use thioesters and form the phosphothioesters in-situ[11, 72]. 
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Raines also reported ligation at non glycyl azides. It was used for the synthesis of RNAse through the 
condensation of three segments RNAse A(1-109) was expressed as a thioester, the dipeptide 
RNAse(110-11) was synthesized as the phosphinothioester and RNAse(112-124) was synthesized as 
the N-terminal azide. The Staudinger ligation was performed directly on solid support after which the 
peptide was cleaved and purified before performing the final NCL to give the full-length RNAse[73]. 
It was also used for synthesis of cyclic proteins by protecting the phosphinothiol with borane which 
allowed the azide group to be added on the same molecule[74]. After protecting groups removal the 
ligation was performed. Lee et al. developed a resin bound phosphorylthiol for the solid phase 
Staudinger ligation. The resin can be recycled for repetitive use. 
 
 
Scheme 1.10: General mechanism of traceless Staudinger ligation 
 
 
1.2.4 Ketoacid Hydroxylamine Ligation 
 Ketoacid-hydroxylamine (KAHA) ligation was developed by Bode et al as an alternative 
method for reagent free peptide bond formation. The method is based on the selective reaction 
between α-ketoacid and hydroxylamine to yield an amide bond in presence of other functional groups 
often found in peptides such as amines, alcohols and carboxylic acid [12]. Two types of KAHA 
ligations with two distinct pathways were defined: type I ligation (scheme 1.11A) occurs between 
peptide α-ketoacids and O-unsubstituted hydroxylamines in polar aprotic solvents (such as DMF or 
DMSO) and peptide concentrations comparable to NCL. Type II ligation (scheme 1.11B) requires O-
substituted hydroxylamines (mostly as O-benzoyl hydroxylamines) and works best at aqueous medium 
and higher peptide concentrations. The benzyl substituted hydroxylamine undergoes elimination 
making their use for ligation problematic. A solution to the labile benzoyl protected hydroxylamine 
came in the form of 5-oxaproline. This building block can be introduced directly during SPPS and 
reacts selectively with ketoacids to give the peptide bond at the ligation site and an unnatural 
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homoserine residue (scheme 1.11C) [75]. Using oxazetidine building block as alternative to 5-
oxaproline also proved successful and allowed the introduction of a serine residue at the ligation 
site[76]. Major advancements in KAHA ligation were the development of SPPS compatible synthesis 
of the peptide α-ketoacids and hydroxylamines [75, 77], the identification of 5-oxaproline as a stable 
hydroxylamine and the ability to mask the ketoacids and hydroxylamines to enable multiple segments 
ligation. The ligation methods have been successfully applied for synthesis of several protein targets 
such as the Pup[75] UFM1 [78] and heme protein Nitrophorin 4 [79].  
Although impressive demonstrations of the method capabilities, KAHA ligation remains a 
non-common practice mainly due to the requirement of DMSO as co-solvent, the somewhat elevated 
temperatures required for ligation of longer peptide fragments, introduction of the unnatural 
homoserine residue as well as the need to purify the ligation products before unmasking of the 
ketoacid and hydroxylamine. 
 
Scheme 1.11: Ketoacid-hydroxylamine ligation. A) type I KAHA ligation; B) type II KAHA ligation; 
C) KAHA ligation employing 5-oxaproline as hydroxylamine derivative. 
 
1.2.5 Solid Phase Chemical Ligation (SPCL) 
 
Most proteins and peptides synthesized nowadays using chemical ligation methods are 
synthesized in solution. As the ligation chemistry is done in aqueous buffers under ambient 
temperatures, working in solution is comfortable as it allows easy and immediate analysis of the 
ligation by chromatography techniques combined with mass analysis and direct purification by 
preparative HPLC with no work-up required prior to it. Despite the advantages of NCL in solution, it 
is still a limited tool for synthesis of larger targets of several dozen kDa in size (largest protein 
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synthesized by pure chemical methods was the 304 amino acid tetraubiquitine). In early years after 
NCL introduction, such an endeavor required purification of the product after each step, not only 
drastically decreasing the yield but also being time consuming. In the recent decade, major advances 
in multi-segment sequential and convergent ligations have been made. Kent and co-workers have 
demonstrated a one-pot ligation of 3 segments of crambin using a thiazolidine (Thz) protection on the 
cysteine of a middle fragments [80]. The Thz protecting group has enjoyed broad use in multi-
segment ligation due to its mild removal conditions and compatibility to ligation conditions [40, 81-
83]. A different approach relies on masked or latent thioesters derivatives that are activated post 
ligation to enable consequent ligations. Examples include the bis(2-sulfenyl)amino (SEA) linker 
1.073 developed by Melnyk [84-86] (scheme 1.12A) or Kent’s kinetically controlled ligation (KCL) 
[87]. Other examples utilizing controlled O→S (scheme 1.12B) or N→S acyl shifts have also been 
presented [41, 88-91]. These attempts, while extending the scope of chemical synthesis of protein, 
have yet to offer a general, universal solution for sequential ligations. 
Having a general tool that enables several ligations to be performed sequentially would 
increase the number of targets achievable through chemical synthesis. For this reason, trials were 
made from very early on to adapt NCL to the solid support medium. The motivation behind these 
trials is clear: utilize the advances SPPS has given to peptide synthesis for the total chemical synthesis 
of proteins. By successfully applying NCL to the solid support one could use large excess of reagent 
to force ligations to completion and easily remove them by simple washing steps, perform 
consecutive reaction, and possibly automatize the process. The principles of SPCL are shown in 
scheme 1.11. A target protein can be assembled by sequential ligation steps on solid support in either 
N→C or C→N direction. First, peptides need to be orthogonally and selectively anchored onto and 
released from the solid support. The direction of the synthesis determines the property of the middle 
fragments. In N→C directed SPCL (scheme 1.13 A) thioesters precursors are utilized (1.081). 
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Scheme 1.12: N→C directional three-segment NCL utilizing crypto thioesters. A) SEAon/off system, 
B) Ligation of peptide O-Esters. 
 
These are activated post-ligation to enable chain elongation (scheme 1.13A 1.083). If the C→N 
direction is chosen, the middle fragments N-termini must be orthogonally protected to allow 
controlled ligation (scheme 1.13B). 
Indeed, several pivotal works have shown the potential of SPCL as a method to synthesize 
proteins with good yields and purity. The group of Kent has released the first strong evidence for the 
methods applicability, synthesizing three proteins of varying length: the 74 amino acid long human 
anaphylatoxin C5a (scheme 1.14A), the 115 amino acid long human MIF protein and the 118 residues 
long GV-PLA2 protein. Syntheses were demonstrated in both N→C as well as C→N directions [92]. 
Melnyk used the SEA linker for SPCL application to synthesize the 136 amino acid long polypeptide 
derived from human hepatocyte growth factor by ligation of 5 segments in a linear fashion [93]. 
Recently the group of Brik has successfully utilized SPCL-desulfurization to synthesize the 124 amino 
acid long H2B protein by condensation of four peptides (scheme 1.14B) [94]. The cysteine residues 
were masked as thiazolidines for selective coupling and following the complete assembly of the 
protein, the unnatural cysteine residues were desulfurized directly on support to yield the native 
alanine residues.  
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Scheme 1.13: General scheme for sequential SPCL. A) N→C direction by using masked thioesters; 
B) C→N direction relying on orthogonal protection. 
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Scheme 1.14: A) Synthesis of the C5a protein in N→C directional sequential SPCL using 
thiocarboxylate as masked thioester. B) Synthesis of H2B protein in a C→N directional sequential 
SPCL utilizing Thz as masked Cys and on resin desulfurization. Msc: methylsulfonylethoxycarbonyl, 
RA: Rink Amide. 
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2 Research Goals 
 
Several methods for extending NCL were developed over the recent years and have expanded 
the scope of NCL greatly. As a result, many new ligation junctions were introduced, giving great 
flexibility for chemists in the field of total chemical synthesis of proteins. Despite the numerous 
ligation junctions available, the goal of enabling NCL at any residue, which would give complete 
synthetic control and access to a wide variety of proteins, is not yet achieved. Moreover, some of the 
methods that were developed do not exhibit the same effectiveness as NCL in terms of ligation time 
and yield, other methods, such as conformationally assisted ligation are extremely specific and are 
useful only in rare cases. The desulfurization technique, although very promising and despite the great 
achievements accomplished through it, enables ligation only at a specific junction and often requires 
laborious synthesis to yield the thiol-handle modified amino acids.. 
The goal of this research was to develop an effective method for peptide ligation that could be 
broadly used for total chemical synthesis of proteins in solution and on solid-support. Auxiliary 
assisted ligation methods have great potential in realizing this vision. An auxiliary can be attached to 
the N-terminus of any peptide, promote ligation at wide range of junctions, and removed to yield the 
native protein. However, the biggest hindrance encountered with auxiliary-assisted NCL was the 
inability to ligate sterically demanding junctions efficiently. The harsh conditions needed to promote 
auxiliary removal from the ligation product is another factor preventing wider application of the 
method as some of the auxiliaries require strong acids such as hydrofluoric acid, TFMSA or TFA 
which are dangerous to handle or are incompatible with frequently occurring post translational 
modifications. To overcome these limitations, an innovative auxiliary that could be effectively and 
easily attached to peptides during SPPS and allow ligation at a broad range of ligation junctions was 
sought after. The auxiliary was designed to be removed from the amide bond following ligation by 
exposing the ligation product to mild basic conditions in aqueous medium and should be compatible 
with unprotected proteins and acid-sensitive post translational modifications.  
In the first part of the work development of such class of auxiliaries is presented and 
discussed. The design and hypothesized mechanism of these auxiliaries is described in scheme 2.1. 
The auxiliaries are based on the 4-mercaptobutanoate attached to the terminal amine via C3. The thiol 
handle is positioned in such a manner as to form the favorable 5-membered ring intermediate, 
mimicking the cysteine role in NCL. The linear butyl scaffold should provide flexibility to the 
auxiliary thus enabling it to promote ligation at hindered junctions. The carboxyl function presents 
several electron withdrawing substituents which increase the acidity of the α-proton. Once a peptide 
bond is formed, cleavage of the auxiliary via elimination was envisioned to take place by exposure to 
mild basic conditions furnishing the native peptide bond and a mercaptobutenoate derivative (scheme 
2.1 path A).  
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During the course of the ongoing PhD work of Simon Loibl, Humboldt University Berlin, 
observations were made that hinted towards auxiliary cleavage by a radical mechanism. In agreement 
with previously suggested radical desulfurization, exposure to oxygen or light could lead to formation 
a thiyl radical 2.3TR. In presence of TCEP, desulfurization may take place to yield the carbon radical 
2.3CR. Fragmentation may lead to the butenoate derivative 2.5 and peptide amide radical 2.6AR 
which would abstract a hydrogen from a hydrogen donor (an amine base) to yield the native peptide 
(scheme 2.1 path B).   
 
 
Scheme 2.1: General scheme depicting the auxiliarystructure and hypothesized removal mechanisms. 
A) ionic mechanism; B) radical mechanism. 
 
 
In the second part of the work the concept of auxiliary assisted NCL was expanded further for 
the first reported application of auxiliary-mediated SPCL using a 2-mercapto-2-phenylethyl auxiliary 
peptide 2.7 (scheme 2.2 A and B)[95]. The auxiliary was developed by Simon Loibl (Humboldt 
University Berlin) on in the work towards dissertation. Similarly to the other auxiliaries, ligation 
undergoes a favorable 5-membered ring transition state as to benefit from its favorable kinetics. Unlike 
the auxiliaries discussed in the first chapter, a non-branched α-carbon at the connection site to the 
peptide gives it higher flexibility and thus improved ligation kinetics and enable ligations at 
demanding sites. The auxiliary was envisioned to be removed in a radical β-fragmentation mechanism 
in presence of TCEP with the phenyl ring acting as a radical stabilizer (scheme 2.2 C). The auxiliary’s 
ability to ligate large peptide fragments on solid support was tested by the synthesis of the MUC1 
variable number tandem repeat (VNTR) domain. Trials in performing sequential ligation of multiple 
fragments on solid support were also done. 
 31 
 
 
Scheme 2.2: General scheme for auxiliary assisted SPCL of the MUC1 VNTR domain. A) N→C 
directed synthesis using masked thioesters; B) C→N directed synthesis using orthogonal thiol 
protection; C) Hypothesized mechanism for auxiliary removal. 
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3 Results and Discussion 
 
3.1 Native Chemical Ligation Assisted by Base-Labile Auxiliaries 
The goal of this work is to broaden the scope of auxiliary mediated native chemical ligation. Nα-
auxiliaries facilitate the ligation reaction through a thiol handle which mimics the cysteine function. A 
specially designed functional group on the auxiliary enables selective cleavage of the auxiliary from 
the ligation product to obtain the native peptide bond. Most of the existing auxiliaries are acid labile 
and differ from each other by the sensitivity to acid and to a degree, the scope of ligation sites 
available by them. This work seeks to develop a new class of auxiliaries, designed to extend the 
number of available ligation junctions and to be removed not by acidic conditions, which are 
incompatible with several protein modifications, but rather by exposure to a mildly basic aqueous 
medium. To fulfill this goal new auxiliaries were designed and synthesized. The auxiliaries possess 
three functional centers: a thiol moiety for promoting the NCL, a functional group that will enable 
selective cleavage off the native peptide bond and a third reactive center for coupling to the amino acid 
or peptide terminal amine. Once the synthesis of the building blocks and auxiliary peptides is 
completed the auxiliaries’ scope and behavior in ligations will be studied on model systems and a 
method for selective and efficient cleavage of the auxiliary from the ligation product to afford the 
native peptide will be developed. To prove the robustness and applicability of the method a longer 
peptide or protein fragment will be synthesized. 
3.1.1 Initial Concept and Design of the Auxiliaries 
The general scheme and design of the auxiliaries is shown in scheme 3.1. The auxiliaries are 
based on a butyrate scaffold. The thiol handle is positioned on the terminal carbon, two carbon atoms 
away from the terminal amine enabling a 5-membered ring transition state (scheme 3.1 3.003) as in 
NCL. The cleavable characteristic of the auxiliary stems from the presence of an electron withdrawing 
group (EWG). The EWG increases the acidity of the α-proton and was envisioned to facilitate the 
auxiliary removal under basic conditions by an elimination mechanism (scheme 3.1 3.004). The bond 
between the auxiliary and the peptide backbone is consequentially cleaved to create two stable 
products: the desired native peptide 3.005 and a ,-unsaturated butanoic acid derivative 3.006. 
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Scheme 3.1: General structure and mechanism of base labile auxiliaries.  
 
The auxiliaries were designed to be attached directly onto the resin bound peptide through 
reductive amination between the terminal amine of the peptide and a ketone functional group on the 
auxiliary precursor. The ability to attach the auxiliary directly to any resin-bound peptide increases the 
general utility of the method by eliminating the need to synthesize individually modified amino acids 
for each specific ligation site. If desired however, the auxiliary can be attached to an amino acid to be 
later used as a monomer for SPPS (scheme 3.2). 
 
Scheme 3.2: Strategy for the synthesis of auxiliary modified peptides. A) Reductive amination on 
solid supported; B) Coupling of auxiliary modified amino acids. 
 
3.1.2 Synthesis of Auxiliary Peptides 
 
Previous results using a cyano moiety as the EWG on the auxiliary have shown that when 
treated with TFA or ligation buffer, the auxiliary spontaneously rearranges into two new species:  
amide 3.014 and thiolactone 3.015[96]. The hypothesized mechanism forming these two species is 
shown in scheme 3.3. An intramolecular attack on the cyano group by the thiol moiety takes place 
leading to the formation of imidothioester 3.013a. This reactive species reacts further in a 1,2-addition 
of water to form the tetrahedral aminothiophene-alcohol 3.013b that  turns either to the amide species 
3.014 or the thiolactone species 3.015 [96].   
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Scheme 3.3: Hypothesized mechanism for the formation of the butanamide 3.014 and thiolactone 
3.015 auxiliaries. 
 
As the cyano auxiliary spontaneously formed the amide and ligation experiments done with 
this auxiliary successfully gave ligation product [96], a study to reach a deeper understanding of the 
behavior of the amide auxiliary for ligation and removal was planned. Three auxiliaries were designed: 
The spontaneously formed amide auxiliary 3.017, the secondary amine N-phenylamide auxiliary 3.018 
and the tertiary N-methyl-N-phenylamide 3.019. The latter two will help in examining the influence 
substitution of the nitrogen has as well as to see the influence of the electron rich benzene ring on the 
ligation kinetics and cleavage of the auxiliary. A fourth auxiliary 3.016, with an ethyl ester as the 
EWG group, was also designed as it was hypothesized to show similar or improved removal properties 
due to the ester’s greater electronegativity in comparison with an amide. 
 
Figure 3.1: General structures of auxiliaries. 
 
3.1.2.1 Synthesis of Auxiliary Precursors 
All auxiliary precursors were synthesized bearing a ketone functionality which would later 
enable the reductive amination between them and the amino acid amine. Auxiliary precursor 3.021 
was synthesized in a straightforward manner starting from ethyl 4-chloro-3-oxobutanoate 3.020 by 
substituting the chloride with tert-butylthiol in the presence of K2CO3 in DMF. After aqueous work up 
the crude was passed through a plug of silica to remove any residual impurities to give the pure 
compound in 85% yield (scheme 3.4).  
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Scheme 3.4: Synthesis of auxiliary precursor 3.021. 
 
Auxiliary precursor 3.024 was synthesized in two steps. Starting from acetoacetamide 3.022, 
bromine was introduced by the unselective bromination- selective debromination reaction [97] 
yielding 4-bromoacetoacetamide 3.023 which was directly converted into the S-tBu protected 4-
thioacetoacetamide 3.024 in 63% yield over two steps. 
 
Scheme 3.5: Synthesis of auxiliary precursor 3.024. 
The synthetic route for auxiliary precursor 3.028 is shown in scheme 3.6A. It is a three step 
synthesis starting from ethyl 4-chloro-3-hydroxybutanoate 3.025. Attempt to introduce the tert-
butylthiol group by employing the conditions used for auxiliary precursor 3.21 led to the formation of 
two products in nearly 1:1 ratio. NMR analysis revealed that the two products are the regioisomers 
3.026a and 3.026b (scheme 3.6B).  
 
Scheme 3.6: A) Synthetic route towards auxiliary precursor 3.028; B) Observed products in reaction 
between 3.025 and tert-butylthiol. 
 
The presence of the two products suggests an initial intramolecular attack of the alcohol on the 
alkyl chloride forming epoxide 3.025* (scheme 3.7). A nucleophilic attack by the thiol on the 4th 
carbon leads to the formation of enantiomer 3.026a (scheme 3.7). The presence of 3.026b might be 
explained by a similar attack on the 3rd carbon, however, this carbon is sterically hindered and an 
attack on this position is unfavorable. Taking into account the thiol nucleophile itself is bulky as well a 
different mechanism may play a role in the formation of 3.026b. A possible route is shown in scheme 
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3.7. After formation of epoxide 3.025* the acidic α-proton is abstracted by a base, opening the epoxide 
and forming the conjugated Michael system ethyl 4-hydroxy-2-butenoate species 3.025*. The Michael 
system is subsequently attacked by the thiol in a 1,4-addition mechanism to give product 3.026b.  
 
Scheme 3.7: Hypothesized mechanisms for generation of products 3.026a and 3.026B through 
epoxide opening. 
To overcome this problem the reaction conditions were slightly altered. First, more 
equivalents of base and thiol were used. In addition, the stronger base[98], cesium carbonate, was 
used. As an added measure the thiol and base were allowed to react for several minutes to pre-form the 
thiolate species before adding chloride 3.025. Under these conditions, a clean conversion to the desired 
product was achieved in quantitative yield. The crude was converted directly into the N-phenylamide 
3.026 through trimethylaluminum amidation of esters [99]. The final step was the formation of the 
ketone. To perform this reaction a mild oxidation reaction that would not oxidize the thioether was 
required. The Dess-Martin periodinane reagent [100] proved to be suitable, leading to a fast and clean 
conversion with excellent yield (scheme 3.8). 
 
Scheme 3.8: Synthesis of auxiliary precursor 3.028. 
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The final precursor 3.031 was synthesized in a similar fashion to auxiliary 3.028. However, a 
direct amidation of the ester was not possible with the secondary, more sterically demanding amine of 
the N-methylaniline (NMA). To this end, ester 3.026 was first hydrolyzed with NaOH in THF and the 
amine was then coupled to the acid using EDC in DMF to give the amide 3.029 with 40% yield. Dess-
Martin oxidation gave the desired ketoamide compound 3.031 in 70% yield (scheme 3.9). 
 
 
Scheme 3.9: Synthesis of auxiliary precursor 3.031. 
With all four auxiliary precursors in hand, the next step, attachment of the auxiliaries on to the 
model peptides by reductive amination, could begin. 
 
3.1.2.2 Reductive Amination on Solid Support 
The model peptidyl resins GRAEYSGLG 3.032 and ARAEYSGLG 3.033 were prepared 
employing routine Fmoc SPPS protocol on a Rink Amide resin (figure. 3.2) 
          
             
Figure 3.2: UPLC analysis of crude model peptides A) GRAEYSGLG 3.032; B) ARAEYSGLG 
3.033; 03-50% B in 20 min. 
 
The auxiliary precursors were coupled to the resin bound peptides by reductive amination. The 
auxiliary precursors were dissolved in 1:1:1 NMP:MeOH:TMOF and 10% v/v acetic acid and added to 
the resin that was pre-swelled in NMP. After 60 min, sodium cyanoborohydride in 1:1 NMP:MeOH 
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was added and the progress of reaction was monitored by HPLC-MS. The analysis showed product 
was forming, however, a major side product was also emerging. Analysis of the reaction revealed N-
acetylation. This unwanted reaction was probably due to a reaction of the amine with the acetic acid. 
To avoid it, the auxiliary precursors in same solvent mixture, were added to the resin and left to react 
for 5 min before adding 5% v/v of acetic acid. Postponing the addition of the acetic acid together with 
halving its volume helped to reduce the amount of N-acetylation drastically. Comparing the efficiency 
of the reductive amination between the four precursors, no startling differences were observed. The N-
methyl-N-phenylamide auxiliary precursor 3.031 has exhibited slightly less favorable reaction profile, 
requiring longer reaction time to reach a satisfactory conversion ratio. However, a major difference 
was seen when reaction was performed on glycine in comparison to alanine. While on the N-terminal 
glycine peptide 3.032 reaction reached 80-90% conversion after 24-48 hr using 10-15 eq. of auxiliary 
precursors, the N-terminal alanine peptide 3.033 required the use of 20-30 eq. and often 3-5 days to 
achieve acceptable conversion to product. In the case of the N-methyl-N-phenylamide precursor 3.031, 
the reaction did not reach more than 60-70% conversion even when allowed to react for extended 
period of times and with fresh batch of auxiliary precursor added. Once reaction was complete or, 
alternatively, did not progress further, the peptide was cleaved from support with a cleavage mixture 
of TFA:H2O:TIS 95:2.5:2.5 v/v to yield the crude S-tBu protected auxiliary peptides (figure 3.3) 
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Figure 3.3: HPLC analysis of reductive amination on resin bound peptides 3.032 and 3.033 to give 
crude N-terminal glycine auxiliary peptides 3.034 (A), 3.036 (B), 3.038 (C), 3.040 (D) and N-terminal 
alanine auxiliary peptides 3.035 (B), 3.037 (F), 3.039 (G),3.041 (H); Peak 3.032* and 3.033* 
corresponds to N-acetylation of peptide 3.032 and 3.033 respectively; peak labeled with * corresponds 
to unassigned masses; 03-60% B in 20min, 210 nm. 
 
3.1.2.3 Deprotection of the tert-Butyl Protection Group 
To remove the tert-butyl group, peptides were first treated with a cold mixture of 
TFA:TFMSA:anisole at 0 °C for 90 min. Under these conditions the auxiliary peptides were divided 
into two groups based on their response to the cleavage mixture. While the N-phenylamide and N-
methyl-N-phenylamide auxiliary peptides 3.038-3.041 yielded the desired fully unprotected auxiliary 
peptides 3.046-3.049 respectively (figure 3.4 C,D,G,H) as the main products, the ethyl ester and amide 
auxiliary peptides 3.034-3.037 formed almost exclusively the thiolactone modified peptides 3.050 and 
3.051 respectively (see p. 116). In an effort to hinder this side reaction, a different procedure for 
removal of the tert-butyl group from peptides 3.034-3.037 was used, employing mercury acetate [101]. 
Under mercury acetate treatment the thiolactone formation was completely inhibited or greatly 
reduced (figure. 3.4 A,B,E,F). 
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Figure 3.4: HPLC analysis of tert-butyl deprotection to give unprotected auxiliary peptides. A) 
reaction of peptide 3.034 to give 3.042; B) reaction of peptide 3.036 to give 3.044; C) reaction of 
peptide 3.038 to give 3.046; D) reaction of peptide 3.040 to give 3.048; E) reaction of peptide 3.035 to 
give 3.043; F) reaction of peptide 3.037 to give 3.045; G) reaction of peptide 3.039 to give 3.047; H) 
reaction of peptide 3.041 to give 3.049; peaks 3.032 and 3.033 correspond to peptides GRAYESGLG 
and ARAEYSGLG respectively; peak 3.032* and 3.033* correspond to N-acetylation of peptide 3.032 
and 3.033 respectively; Gradient A-C, E,F,H: 03-60% B in 20min, Gradient D, G: 03-40% B in 20 
min, 210 nm. 
 
As seen in figure 3.4 the removal of the thiol protecting group from ethyl ester auxiliary 
peptides 3.034-3.035, the N-terminal glycine amide auxiliary peptide 3.036 and N-phenylamide and 
N-methyl-N-phenylamide auxiliary peptides 3.038-3.041 gave a direct conversion from starting 
material to product with impurities stemming from incomplete reductive amination of peptides 
GRAEYSGLG 3.032 or ARAEYSGLG 3.033 as well as the respective N-acetylated derivatives 
3.032* and 3.033*. The removal of tert-butyl group from the N-terminal alanine amide auxiliary 
peptide 3.037 resulted in formation of thiolactone peptide 3.051 (figure 3.4 F) demonstrating the 
instability of the amide auxiliary.  
Figure 3.4 E shows the HPLC analysis of crude material obtained after S-tBu removal from 
ethyl ester auxiliary peptide 3.035. In this trace, a double peak for product 3.043 is observed. Mass 
analysis showed the two peaks to have identical mass corresponding to the desired product 3.043. The 
double peak probably is the result of two diastereomers formed during reductive amination. As the 
reductive amination is non-stereospecific both possible diastereomers will be formed (scheme 3.10). 
Interestingly, the differentiation into two peaks is not always observed.  
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Scheme 3.10: Evolvement of R,S- and S,S-enantiomers during reductive amination. 
 
The auxiliary peptides were purified on a preparative HPLC to yield the pure auxiliary peptides 3.042-
3.049 ready for ligation experiments. Yields and mass analysis for each of the auxiliary peptides is 
shown in table 1. 
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Table 1: Mass analysis and isolated yields for tert-butyl removal from peptides 3.034-3.041 to 
give peptide auxiliaries 3.042-3.049 
Identity Entry Peak 
Observed 
Mass (Da) 
Calculated 
Mass (Da) 
Isolated 
Yield 
CO2Et (G) A 
3.032 907.7 908.0  
30% 3.042 1053.8 1054.2 
CONH2 (G) B 
3.032 907.7 908.0 
 
 
24% 
  
3.032* 
949.8 950.0 
3.044 1024.8 1025.2 
CONHPh (G) C 
3.032 907.7 908.0 
 
 
 
36% 
  
3.032* 
949.8 950.0 
3.050 1007.7 1008.2 
3.046 1100.9 1101.3 
CONMePh (G) D 
  
3.032* 
949.8 950.8 
 
16% 3.048 1114.9 1115.9 
3.040 1171.0 1171.4 
CO2Et (A) E 
3.033 921.7 922.0  
14% 3.043 1067.8 1068.2 
CONH2 (A) F 
3.033 921.7 922.0  
 
 
18% 
3.045 1038.6 1039.2 
3.051 1021.6 1022.1 
3.037 1094.9 1095.3 
CONHPh (A) G 
3.033 921.7 922.0 
 
 
 
15% 
  
3.033* 
963.7 964.0 
3.051 1021.8 1022.1 
3.047 1114.8 1115.3 
CONMePh (A) H 
3.033 921.8 922.0  
15% 3.049 1128.8 1129.3 
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3.1.3 Ligation Experiments 
With the auxiliary peptides in hand ligation studies begun,. Ligations were performed at a 
concentration of 5 mM in 100 mM phosphate buffer pH 7.5 at 25 °C with 20 mM TCEP and 3% 
thiophenol as additives. Reactions were monitored using UPLC-MS. 
3.1.3.1 Ligations at Glycine-Glycine Junction 
 
 
 
Figure 3.5: UPLC analysis of ligation between LYRAG thioester 3.052 and auxiliary peptides 3.042 
(A), 3.044 (B), 3.046 (C) and 3.048(D). 3.032 GRAEYSGLG, 3.050: Thiolactone-GRAEYSGLG, 
peaks labeled with * correspond to unassigned masses; 03-60% B in 6 min, 210 nm. 
 
 Figure 3.5 shows the UPLC analyses of ligations between the four auxiliary peptides 3.042, 
3.044, 3.046 and 3.048 with thioester 3.052. Two product classes can be observed: ligation product 
and derivatives of it (double N- and S-acetylated ligation product marked Xa and thiolactone species 
marked XTL) and peptide GRAYESGLG 3.032. These products are formed as a result of two 
competing reactions: auxiliary mediated NCL and removal of auxiliary from auxiliary peptides. The 
factors determining the outcome of the ligation are therefore rate of ligation vs. rate of auxiliary 
cleavage to form the native unmodified peptide 3.032. Plotting the time vs. yield of the four reactions 
and estimating the initial rate constants shows that except the distinctly slower N-methyl-N-
phenylamide auxiliary peptide 3.048, the difference in initial reaction rates between ethyl ester 3.042, 
amide 3.044 and N-phenylamide  3.046 auxiliary peptides are negligible, ranging from 0.03-0.04 M-1s-
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1 (figure 3.6 A). This means that it is the rate of the auxiliary removal that governs the achievable 
yields of auxiliary modified ligation product. By examining the UPLC traces for reactions systems 
analyzed immediately after reagent mixing (t = 0 min in fig. 3.5) one sees that ethyl ester 3.042 and N-
phenylamide 3.046 auxiliary peptides are stable (figure 3.5 A,C), while amide 3.044 and N-methyl-N-
phenylamide 3.048 auxiliary peptides give a 1:1 mixture of thiolactone peptide 3.050 and auxiliary 
peptide (figure 3.5 B,D). A closer inspection of the ligation progress hinted that the thiolactone species 
is being formed over time. Once formed it does not participate in ligation but instead rapidly 
decomposes to give unmodified peptide 3.032. To prove this, ligation with thiolactone peptide 3.050 
was conducted, clearly demonstrating its removal to yield peptide 3.032 as a single product (figure 3.6 
B). The propensity to form the thiolactone is especially prominent with the amide and the N-methyl-
N-phenylamide auxiliaries 3.044 and 3.046 but is not exclusive to them. Thiolactone is also seen with 
the N-phenylamide auxiliary 3.045 albeit in low concentrations. Thiolactonisation also occurs on the 
ligation product (figure3.5 B-D 54TL). Ligation products 3.054 and 3.060 were purified by semi-
preparative HPLC with isolated yield of 56% each. The ligation products 3.058 and 3.064 were not 
isolated due to the poor behavior exhibited by these auxiliaries making them unsuitable for auxiliary 
assisted ligation. 
 
 
Figure 3.6: A) time vs. yield and initial rate constants of ligation between thioester 3.052 and auxiliary 
peptides 3.042, 3.044, 3.046, 3.048; B) UPLC analysis of reaction between thioester 3.052 and 
thiolactone peptide 3.050 at 0 hr and 2 hr; C) Scheme of products formed during reaction between 
peptide thioester 3.052 and thiolactone peptide 3.050; peaks labeled with * correspond to unassigned 
masses; 03-60% B in 6 min, 210 nm. 
3.1.3.2 Ligation at Alanine-Glycine Junction  
Experiments at Ala-Gly junction further emphasized the behavior observed at the Gly-Gly 
junction. The increased sterical demand of this junction lowered the rate of ligation significantly 
increasing the formation of GRAEYSGLG peptide 3.032 in all cases with conversion of ~10% for 
ethyl ester and N-phenylamide auxiliary peptides 3.042 and 3.046 and ~35% for amide and N-methyl-
N-phenylamide peptides 3.044 and 3.048 according to integration (figure 3.7). Ethyl ester auxiliary 
peptide 3.042 and N-phenylamide auxiliary peptide 3.046 showed 65% and 80% conversion to ligation 
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product respectively after 4 hr and isolated yields of 40% for ethyl ester auxiliary 3.055 and 37% for 
N-phenylamide auxiliary 3.061 (figure 3.8 A and C). Ligation with peptides 3.044 and 3.048, 
however, became impractical due to their tendency to rapidly form the thiolactone derivative 3.050 
and less than 30% conversion to ligation product observed in both reactions (figure 3.8 B and D).  
 
 
Figure 3.7: UPLC analysis of ligation between LYRAA thioester 3.053 and auxiliary peptide 3.042 
(A), 3.044 (B), 3.046 (C), and 3.048 (D); 3.032: GRAEYSGLG, 3.050: Thiolactone GRAEYSGLG, 
TE-OH: LYRAA-OH; peak labeled with * correspond to unassigned masses; 03-60% B in 6 min, 210 
nm. 
 
Calculation of the initial reaction rates demonstrated the strong influence the added sterics had 
on ligation with an astonishing 2 orders of magnitude for N-methyl-N-phenylamide auxiliary peptide 
3.048 (figure 3.8). With the poor results achieved with amide auxiliary peptide 3.044 and N-methyl-N-
phenylamide auxiliary peptide 3.048, due to their tendency to convert to the inactive thiolactone 
species, they have been discarded from further experimentation. 
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Figure 3.8: time vs. yield plot and initial rate constants of ligation between LYRAA thioester 3.053 
and auxiliary peptides 3.042, 3.044, 3.046, 3.048 to give ligation products 3.055, 3.059, 3.061 and 
3.065 repectively 
 
3.1.3.3 Ligation at Glycine-Alanine and Alanine-Alanine Junctions 
Comparing the Gly-Ala junction to its “mirror image”, the Ala-Gly junction (figure 3.9), 
shows that the ethyl ester auxiliary 3.016 and the N-phenylamide auxiliary 3.018 are still able to 
promote ligation between the two peptide fragments. However, the added sterical hindrance on the 
auxiliary peptide had a greater effect on rate and yield of the ligation than in the previous case, when 
the increased sterical demand was located on the thioester fragment. The rate is halved for the ethyl 
ester auxiliary peptide 3.043 and is more than 80% slower for the N-phenylamide auxiliary 3.047. The 
conversion to ligation product is 50% of the value measured for the Ala-Gly junction and isolated 
yields were 10% for ligation product 3.056 (CO2Et) and 15% for ligation product 3.062 (CONHPh). 
With the Ala-Ala junction the scope of the auxiliaries is reached. In this junction, the sterical 
demand is too high to enable the S→N acyl shift and no product formation occurs (figure 3.10). 
Examination of the ligation progress over time reveals the formation of transthioesterification 
intermediate followed by hydrolysis to yield the hydrolyzed thioester and the auxiliary peptide. The 
latter disassemble via the thiolactone to give peptide ARAEYSGLG 3.033 as already observed before 
(figure 3.9). 
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Figure 3.9: UPLC analysis of ligation between LYRAG thioester 3.052 and auxiliary peptides 3.043 
(A) and 3.047 (B); C) Time vs. yield and initial rate constants for the ligation A B; 3.033: 
ARAEYSGLG, 3.051: Thiolactone ARAEYSGLG (TL), TE-OH: LYRAG-OH; peak labeled with * 
correspond to unassigned masses; 03-60% B in 6 min, 210 nm. 
 
The inability of the auxiliaries to mediate the ligation at the Ala-Ala junction can be explained 
by the kinetic profile of auxiliary assisted NCL. Unlike NCL, where transthioesterification is the rate 
determining step, auxiliary assisted NCL rate is dictated by the S→N acyl shift as indicated by the 
detection of the thioester intermediate. Analyzing the ligation, one sees a rapid disappearance of 
starting materials and accumulation of the thioester intermediate 3.063* which consequently 
rearranges to give the ligation product (Figure 3.10 A). Due to the auxiliary added sterical hindrance 
on the amine, the S→N acyl shift becomes very sluggish or completely blocked. Under these 
conditions only the removal of the auxiliary takes place leading to peptide 3.033 being the major 
product of the reaction. 
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Figure 3.10: UPLC analysis of ligation between LYRAA thioester 3.053 and auxiliary peptides 3.043 
(A) and 3.047 (B); C) Scheme of reaction between auxiliary peptide 3.043 or 3.047 with thioester 
3.053; 3.051: Thiolactone ARAEYSGLG (TL), TE-OH: LYRAG-OH, 03-60% B in 6 min, 210 nm. 
 
3.1.3.4 Premature Removal of Auxiliary 
In all ligation studies the removal of the auxiliary from the auxiliary peptide was observed. 
According to the working hypothesis that was the basis of the initial design, the auxiliary should have 
remained stable on the amine, only turning labile once an amide bond is formed. The principle behind 
this assumption was that the amine, being a base, is a very poor leaving group while the poorly basic 
amide makes for a good leaving group. This characteristic was the working principle for previous Nα-
auxiliaries. In the cases studied here, however, an opposite tendency was observed: the auxiliaries 
were removed from the unreacted auxiliary peptides but once the amide bond has been formed the 
auxiliaries’ stability seemed to increase (as no auxiliary-free ligation product was detected).  
The formation of the thiolactone was especially prominent for amide auxiliary 3.017 and N-
methyl-N-phenylamide auxiliary 3.019 which undergo cyclization even at storage as seen in the time 
zero chromatograms where roughly a 1:1 ratio between the linear and cyclic auxiliary peptides was 
observed (figure 3.5 B and D and figure 3.11).  
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Figure 3.11: Scheme and UPLC analysis of ligation between thioester 3.053 and auxiliary peptides 
3.048. 03-60% B in 6 min, 210 nm. 
 
The observation that the stability of the auxiliaries is higher once an amide bond has been 
formed may be the result of amine protonation forming the ammonium salt,. The much less basic 
amide is not protonated under the ligation conditions resulting in the observed stability of the auxiliary 
once ligation product was formed (scheme 3.11 A). This pathway also provides an explanation to the 
cyclic auxiliary higher elimination rate as it locks the amine and the α-proton in an anti configuration 
required for an E2 mechanism (scheme 3.11 B). 
 
Scheme 3.11:.A) Premature cleavage of the auxiliary triggered by protonation of the amine to from thr 
ammonium salt; B) Thiolactone formation locks the ammonium and hydrogen in required anti-
conformation for E2 elimination.  
As long as the sterical demand at the ligation junction was low and formation of ligation 
product rapid, the presence of these species remained negligible. However, even a slight increase in 
sterical demand led to major formation of peptides 3.032 or 3.033 with the effect becoming more 
prominent when the added sterical hindrance was located on the auxiliary peptide. 
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In these cases a thioester intermediate was detected (Figure 3.10 A peak 63*) but failed to 
rearrange to give the native peptide bond fast. It consequently dissociated back to the two peptide 
fragments either by hydrolysis or thiolysis. The auxiliary peptide reacted intramolecular to form the 
highly favorable 5-memberd ring thiolactone that cannot participate in ligation and decomposes to 
give the unmodified peptides. A hypothesized pathway for formation of all seen products is shown in 
scheme 3.12. 
 
Scheme 3.12: Hypothesized pathway of auxiliary-assisted NCL yielding all observed species. 
 
3.1.3.5 Ligation Experiments Summary 
The ligation studies have shown all four auxiliaries to share a similar behavior. As long as the 
steric limitation remained low the ligations proceeded well to yield product with high conversion and 
good isolated yields. The auxiliaries were capable to promote ligation as long as the ligation junction 
contained glycine residues albeit with a drastic decrease in rate and product formation in more 
sterically demanding sites. The limit of the auxiliary ability to promote ligation was met when Ala-Ala 
junction was tried. In this case the S→N acyl shift is not possible due to the combined steric hindrance 
of the auxiliary backbone and the alanine residues methyl groups.  In this regard, the auxiliaries 
discussed here exhibit similar reactivity as previously published auxiliaries [102].  
Despite a design concept based on a linear butyrate scaffold aimed to give the auxiliaries 
flexibility and thus extend the scope of junctions that can be ligated with their assistance, the 
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auxiliaries failed to promote ligation at sterically hindered junctions. The suggested explanation for 
this is the different kinetic profile of NCL and auxiliary-assisted NCL. In NCL the rate determining 
step is the transthioesterification while in auxiliary assisted ligations it is the thioester rearrangement 
to give the native peptide bond that is rate limiting. This kinetic characteristic of auxiliary assisted 
ligations is well known[102], and is most likely due to the secondary amine increased sterical 
hindrance. The auxiliaries presented here all share a common scaffold with a tertiary carbon attached 
to the terminal amine. As shown in NCL[23] and other published works extending NCL such as 
ligation at valine[36], ligations are highly susceptible to sterical hindrances slowing the reaction 
drastically or preventing the reaction to occur altogether. Here, the bulkiness of the auxiliaries 
prevents the S→N acyl shift when the sterical demand of the ligation site increases. Peptide auxiliaries 
with a non-branched structure adjacent to the amine have proven to be highly effective in ligation of 
sterically hindered junctions [95].  
The auxiliaries have a characteristic that hampers their usability: the auxiliaries’ lability under 
ligation conditions. A peak corresponding to GRAEYSGLG peptide 3.032 or ARAEYSGLG peptide 
3.033 is observed with varying abundance in all ligations performed. These peptides were formed due 
to the removal of the auxiliary seemingly in a two-step fashion: a slow cyclization step gives the 
thiolactone species, followed by elimination of the thiolactone. The cyclization reaction differs 
between the auxiliaries. The tendency to cyclize is highest for the amide auxiliary 3.017, followed by 
the N-methyl-N-phenylamide 3.019, the N-phenylamide auxiliary 3.018 and last the ethyl ester 
auxiliary 3.016. While not proven, a removal directly from the linear form probably takes place as 
well. Interestingly, under ligation conditions the auxiliaries remain stable once ligation product was 
formed. 
As the auxiliary removal is a competing reaction to the ligation, the factor determining which 
path becomes prominent, ligation product formation or removal of auxiliary to give peptide 3.032 or 
3.033, is determined by the rate difference between the S→N acyl shift and the cyclization to 
thiolactone. As the ligation junction hindrance increases the acyl rearrangement rate decreases making 
the auxiliary removal route the dominant path. 
Despite the auxiliaries’ lability and inability to excess sterically demanding junctions, the ethyl 
ester auxiliary 3.021 and the N-phenylamide auxiliary 3.028 showed most promise, exhibiting higher 
stability, faster reaction rates and less side product formation. Auxiliaries 3.024 and 3.031 were 
discarded from further investigation due to their instability. Both auxiliary 3.021 and 3.028 showed 
good results during the ligation studies with highest rate, stability and ligation product formation. 
Additionally, the premature removal of the auxiliaries from the auxiliary peptides shows that cleavage 
under mild conditions is feasible and hence, it should be possible to cleave the auxiliaries from the 
ligation product. For this reason the next stage, finding removal conditions for the auxiliaries from 
ligation product, was investigated with auxiliary 3.021 and 3.028. 
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3.1.4 Removal of Auxiliary 
The ligation studied with the model peptides have shown that the auxiliaries do indeed seem to 
be labile to basic conditions as hinted by the auxiliaries’ premature removal from the auxiliary 
peptides. With the observation that the amide bond increases the stability between the auxiliary and 
the peptide a higher pH value and possibly higher temperature might be necessary to achieve efficient 
cleavage of the auxiliary. 
First tests were performed using either pure ligation product 3.054 (or a mixture of 3.054 and the N- 
and S-acetylated ligation product 3.054a). The peptides were dissolved in an aqueous buffers of 50 
mM glycine to a concentration of 2 mM and the pH was adjusted to 9.0, 10.0 and 10.5 with 0.2 M 
NaOH solution. The mixtures were incubated at 50 °C and 60 °C for 5 hr. A single sample at pH 10.0 
was also tested at 80 °C. As can be seen in figure 3.12, no desired product was detected. Observed 
masses corresponded to disulfide formation and thioester hydrolysis stemming from hydrolysis of 
peptide 3.054a (the S-acylataled ligation product). At 80 °C reaction temperature, peaks with 
unidentified masses were detected- most possibly fragmentation of the peptide induced by high 
temperature and pH values. The disulfide proved to be a stable product and did not react further. The 
stability of the disulfide towards auxiliary cleavage points towards the involvement of the thiyl 
radicaly in the radical pathway (scheme 2.1). 
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Figure 3.12: UPLC analysis of reaction of peptide 3.054 and 3.054a under treatment with auxiliary 
removal buffer at different temperature and pH values after 5 hr. A) Starting material reference; B) 50 
°C pH 9.0 (left), pH 10.0 (middle), pH 10.5 (right); C) 60 °C pH 9.0 (left), pH 10.0 (middle), pH 10.5 
(right); TE-OH: LYRAG-OH, peaks labeled with * correspond to unassigned masses; 03-60% B in 6 
min, 210 nm. 
 
With the observation of a stable disulfide species, experiments were repeated adding 20 mM 
TCEP to the removal buffer. In addition, three amine bases were tested: piperidine, morpholine and 
ethyldimethylamine (EDMA). Aqueous solution containing 160 mM amine and 40 mM TCEP with 
pH value of 8.5-9.0 depending on the amine were prepared. Peptide 3.054 was dissolved to a 
concentration of 2 mM and incubated at 80 °C. As seen in figure 3.13 the treatment with NaOH and 
EDMA failed to yield the desired native peptide. Morpholine and piperidine both gave positive results 
yielding desired native peptide 3.068. Importantly, no aminolysis of the ester was observed.  
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Figure 3.13: UPLC analysis of the reaction of peptide 3.054 under different auxiliary removal buffers 
to yield native peptide 3.068 after 5 hr; Peak * correspond to unassigned masses; 03-60% B in 6 min, 
210 nm. 
The removal of the auxiliary could be achieved via the previously suggested ionic mechanism, 
making removal from the amide bond possible by increased temperature and pH. However, the 
observation that it is the less basic morpholine and piperidine bases which showed the ability to cleave 
the auxiliary, raised a suspicion that the removal of the auxiliary from the ligation product does not 
proceed through an ionic mechanism, as was probably the case for the premature removal of the 
auxiliary. Several observations support a different pathway is for the removal of the auxiliary from the 
ligation product. 
The conditions for the removal, i.e. secondary amine base and necessity of TCEP as additive 
suggest a non-ionic pathway. Auxiliary cleavage experiments under same conditions but with addition 
of thiophenol, a potent radical scavenger, failed to promote auxiliary cleavage. These observations add 
up to results gained with the 2-mercapto-2-phenyl auxiliary[95] and strongly suggest auxiliary 
cleavage via a radical mechanism.  
The possible mechanism is shown in scheme 3.13. Light or oxygen could trigger formation of 
a thiyl radical 3.004TR. TCEP induced desulfurization leads to alkyl radical 3,004AR, which 
fragments to give the amide radical ligation product 3.005AmR and the cleaved auxiliary as a Michael 
acceptor. The amide radical could then be scavenged by the poorer amine hydrogen donors such as 
piperidine or morpholine. 
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Scheme 3.13: Suggested mechanisms for cleavage of auxiliary from ligation product via a radical 
mechanism 
With positive preliminary results, optimization of the conditions required for the removal was 
evaluated. Two aspects were tested: the amine component and the temperature. To do so peptide 3.054 
was dissolved in a buffer containing 160 mM of either piperidine or morpholine and 40 mM TCEP 
and incubated at 50 °C or 65 °C (figure 3.14). Analysis of the crude reaction mixture showed removal 
took place in all cases. Piperidine, being more basic, showed around 70% conversion to product at 
50°C and complete conversion at 65 °C after 5 hr. Morpholine exhibited a moderate reaction rate with 
roughly 50% conversion at 50 °C and 90% at 65 °C after 5 hr. However, morpholine seemed to 
provide a chemoselectivity as judged from the higher purity of crude materials. 
As morpholine proved a milder reagent, forming less side products the piperidine was 
discarded and temperature optimization experiments were performed. The peptides were incubated at 
40, 50 and 60 °C and checked at 2, 4, 6 and 24 hr. As seen in figure 3.15, the auxiliary is removable at 
all temperatures, however, the removal rate is drastically affected. At 40 °C product formation was 
first observed after 6 hr and complete conversion achieved after 24 hr. In comparison, after 6 hr at 60 
°C reaction was >95% complete. Shorter exposure to the buffer and elevated temperature resulted in a 
higher crude purity. 
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Figure 3.14: UPLC analysis of peptide 3.054 under treatment with auxiliary removal buffers 
containing piperidine (A) or morpholine (B) at different temperatures to yield native peptide 3.068 
after 5 hr; Peak labeled with * correspond to unassigned masses; 03-60% B in 6 min, 210 nm. 
 
 
 
Figure 3.15: UPLC analysis showing the advancement of the removal of auxiliary from ligation 
product 3.054 to give native peptide 3.068 at 40 °C (A), 50 °C (B) and 60 °C (C). Peak labeled with * 
corresponds to unassigned masses; 03-60% B in 6 min, 210 nm. 
 
Finding removal conditions that promoted mild and selective removal of the auxiliary, the 
reaction was repeated on ligation products 3.054, 3.055 (CO2Et), 3.060 and 3.061 (CONHPh) on a 
preparative scale. The peptides were dissolved in a buffer of morpholine and TCEP and incubated at 
60 °C. After 6 hr complete conversion was observed from ligation products 3.054 and 3.055 and after 
semi-preparative HPLC purification peptides 3.068 and 3.069 were isolated with 43% and 45% yield 
respectively (figure 3.16).  
Compounds 3.060 and 3.061 required longer treatment of between 7-9 hr (figure 3.17). The 
removal of N-phenylamide auxiliary 3.28 also resulted in lower crude purity with numerous 
unidentified peaks forming. The unmodified peptides 3.068 and 3.069 were isolated with 35% and 
30% yield. 
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Figure 3.16: UPLC analysis showing the removal of auxiliary from ligation product 3.054 to give 
native peptide 3.068 (A) and from ligation product 3.055 to give native peptide 3.069 (B) at 0 and 6 
hr; Gradient: 03-60% B in 4 min, 210 nm. 
 
A X= G         B X= A 
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Figure 3.17: UPLC analysis showing the removal of auxiliary from ligation product 3.060 to give 
native peptide 3.068 (A) and from ligation product 3.061 to give native peptide 3.069 (B) at 0 and 6 
hr; Gradient: 03-60% B in 4 min, 210 nm. 
The experiments have shown both ethyl ester auxiliary 3.021 and N-phenylamide auxiliary 
3.028 can be cleaved from ligation product to yield the unmodified peptide. However, auxiliary 3.021 
gave better yields and produced fewer side products during removal. In addition it has a simpler and 
straightforward synthesis making it the favorable option to use between the two auxiliaries. For these 
advantages over auxiliary 3.028, it was decided to continue to the final step of the study, the synthesis 
of a full-length biologically relevant target, using auxiliary 3.021 only. 
 
3.1.5 Changing the Thiol Protecting Group for Improved Protecting 
Groups Chemistry 
The tert-butyl protecting group used during the model studies has several disadvantages. Besides 
having a foul odor it is stable to treatment with TFA and thus, requires an extra deprotection step by 
treatment with the highly corrosive TFMSA or mercury acetate which is highly toxic. The added 
treatment also reduces yield of isolated products and takes longer time to have the final compound in 
hand. Before pursuing the synthesis of a full length protein an optimized synthesis route was sought 
after. Two protecting groups stood out as possible alternatives; the triphenylmethyl group (Trt), 
removed with 90% TFA treatment and alkyldisulfides which are removed under reductive conditions 
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used in ligation. From the two, the triphenylmethyl group was favored for its straightforward synthesis 
route, as the precursor molecule triphenylmethylmercaptan is commercially available. 
 
 
Scheme 3.14: Synthesis of ethyl 3-oxo-4-(tritylthio)butanoate auxiliary precursor 3.070 
The trityl protected auxiliary precursor 3.070 was synthesized in a straightforward manner 
similar to the synthesis of the tert-Butyl protected auxiliary precursor 3.021 and was isolated with 80% 
yield (scheme 3.13). Coupling to resin bound peptide 3.32 and 3.33 using the same conditions used for 
the previous auxiliary precursors (i.e. 10 eq. of auxiliary in NMP, methanol and trimethylorthoformate 
(TMOF) with 5% v/v AcOH) failed to yield the desired product, most probably due to the increased 
bulkiness of the Trt group. To push the reaction 50 eq. of the auxiliary had to be added to the resin for 
the glycine peptide 3.32 and 75-100 eq. for the alanine peptide 3.33. 
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Figure 3.18: HPLC analysis showing the solid support reductive amination reaction of compound 
3.070 after 48 hr. A) Reaction with peptide 3.032; B) Reaction with peptide 3.033; 3.032*: N-
acetylation of GRAEYSGLG 3.032, 3.033*: N-acetylation of peptide 3.033; Double peak 3.072 
corresponds to the two diastereomers; 03-60% B in 20 min. 
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3.1.6 Total Chemical Synthesis of DCD-1L 
3.1.6.1 The Dermicidin System 
Dermicidin is a 101 residues long protein encoded by the DCD gene. While normally 
restrictedly expressed in eccrine sweat glands of the skin [103] and in certain parts of the brain [104], 
overexpression of dermicidin is reported in multiple human tumor types such as cutaneous tumors, 
melanoma, pancreatic, breast, prostate, and hepatocellular carcinomas [104-111]. The 11 kDa full 
length dermicidin protein and proteolytic peptides derived from it have been proposed to have diverse 
biological functions including growth and survival factor in breast cancer [104] and in neural cells 
[103, 112-115], displaying antibacterial activity [103, 114, 115], and inducing cancer associated 
cachexia [116, 117]. A recent study also demonstrated that dermicidin may function as a proteolytic 
enzyme which can promote tumor cell invasion [118]. 
MRFMTLLFLTALAGALVCAYDPEAASAPGSGNPCHEASAAQKENAGEDPGLARQAPKPRKQRSSLLEKGLDGAKK
AVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL 
 
Figure 3.19: Survival evasion peptide domain and antimicrobial peptide domain  sequence of 
Dermicidin. 
 
Dermicidin belongs to a family of antimicrobial peptides (AMPs), also known as host-defense 
peptides. This family of peptides plays an important role in the innate immune defense of epithelial 
barriers. AMPs show a broad activity against a wide range of photogenes including gram positive and 
negative bacteria, fungi and envelope viruses[119]. It is processed into mature peptides, the most 
important are DCD-1L, DCD-1 and SSL25. It shares no homology with other known AMPs and is an 
unstructured random coil at its secreted state. Unlike most AMPs which are cationic, DCD-1L is 
unique for being anionic with a net charge of -2 at physiological pH. 
Giving the AMPs important role in the immune response as well as their involvement in 
several inner cellular signal transduction pathways, a method to produce pure homogenic samples of 
DCD-1L and other AMPs can help the field of cell biology, immunology, chemical biology or 
microbiology in studying these systems. As many antimicrobial proteins lack a cysteine residue but 
possess several Gly-Gly junctions [120], auxiliary-mediated NCL can be a helpful tool for synthesis of 
large amounts or libraries of AMPs. Herein the presented ethyl 4-mecaptobutyrate auxiliary 3.070, 
which is readily synthesized from inexpensive, commercially available starting materials and is easily 
introduced directly onto the polymer bound peptide, was utilized for the synthesis of the 48 residues 
long DCD-1L. 
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3.1.6.2 Synthetic Route towards DCD-1L 
Scheme 3.15 shows the sequence and synthetic strategy towards the total chemical synthesis 
of the 48 amino acid long DCD-1L peptide. The peptide contains no cysteine residues but possesses a 
Gly78-Gly79 junction making it an ideal target to test the auxiliary-assisted native chemical ligation 
strategy. 
The thioester fragment Der1 was synthesized employing the safety-catch linker strategy[121] 
(figure 3.20). In this method the peptide was synthesized according to the Fmoc strategy on a 
sulfonamide linker. After completion of the synthesis the sulfonamide was activated by treatment with 
trimethylsilyldiazomethane. The peptide was cleaved from support by thiolysis with benzyl mercaptan 
and protecting groups were removed by treatment with TFA to yield the crude unprotected thioester. 
The crude was purified on a preparative HPLC to yield Der1 in 35% yield. 
 
Scheme 3.15: Sequence and synthetic route towards DCD-1L. 
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Figure 3.20: Synthesis of Der1. UPLC-MS analysis of pure Der1. 03-60% B in 6 min, 210 nm. 
 
Der2 was prepared employing Fmoc strategy on a Rink Amide resin. After synthesis was 
complete auxiliary precursor 3.69 was attached directly onto the resin bound peptide using the 
previously described reductive amination on solid support method. A significant amount of acetylated 
peptide was detected, reducing the yields of the final product. Peptide was cleaved and all protecting 
groups removed using standard TFA cleavage and crude was purified on a preparative HPLC to yield 
the pure peptide Der2 in 10% yield (figure 3.21). 
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Figure 3.21: UPLC analysis of crude (A) and pure (B) Aux-Der(78-110) Der2. Peak * corresponds to 
acetylation of amine. Gradient crude: 03-90% B in 6 min; Gradient pure: 03-70% B in 6 min, 210 nm. 
 
3.1.6.3 Total Chemical Synthesis of DCD-1L by Auxiliary-Assisted Native Chemical 
Ligation 
The ligation between Der1 and Der 2 was carried out in a similar fashion to the model study. 
The peptides were dissolved in a phosphate buffer containing 20 mM TCEP, 2% v/v thiophenol to a 
concentration of 5 mM and incubated at 25 °C. After 7 hr ligation was complete and the ligation 
product Der12 was isolated in 50 % yield. To remove the auxiliary a protocol optimized by Simon 
Loibl (ongoing thesis work, Humboldt University Berlin) was applied, using higher concentrations of 
morpholine and TCEP. Pure ligation product Der12 was dissolved in aqueous buffer containing 400 
mM morpholine and 100 mM TCEP to a concentration of 1-2 mM and incubated at 50 °C for 6 hr 
after which UPLC-MS analysis showed a complete removal of the auxiliary. The native peptide was 
purified on a semi-preparative HPLC to yield the pure DCD-1L peptide with 40 % yield (figure 3.22).  
 
 65 
 
 
Figure 3.22: Synthesis of DCD-1L. A) Scheme depicting synthetic route; B) UPLC analysis of 
ligation between Der1 and Der2 and auxiliary removal to yield native DCD-1L. 
 
3.1.7 Conclusions 
In this work a new class of Nα-auxiliaries for auxiliary mediated NCL was described. The 
auxiliaries were envisioned to advance the field in several aspects: 
1. Broaden the scope of synthetic targets available through auxiliary assisted NCL by designing a 
flexible scaffold that would allow ligation in sterically demanding junctions. As previously 
published auxiliaries failed to promote ligation at sterically demanding junctions the field of 
auxiliary mediated ligation did not mature to the level of some other methods such as the 
desulfurization method which enjoy high usability and important application.  
2. Develop an auxiliary that could be removed under mild basic conditions, avoiding the acidic 
conditions used in the available auxiliaries. Acidic conditions induce an N→S acyl shift, 
reversing the ligation direction and more importantly are incompatible with a variety of post 
translational modifications, a fast growing field with its impact and importance only beginning 
to unravel.  
3. Inexpensive, readily synthesized auxiliaries and straightforward coupling to a peptide. While 
not detrimental, such features would increase the applicability and generality of the method, 
enlarging its penetration and application to the scientific community. 
The ligation studies on model peptides have shown that the auxiliaries developed were unable to 
promote ligation at the Ala-Ala junction. This result shows that despite using a linear, flexible scaffold 
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the amine was still too hindered as the amine has two branched alkyl substituents, blocking the S→N 
acyl shift. 
A second disadvantage of the auxiliaries is their instability. Under conditions of NCL the 
auxiliary peptides were unstable and the auxiliary was cleaved to produce native peptides 
GRAEYSGLG 3.032 or ARAEYSGLG 3.033. This undesired side reaction varied between the four 
auxiliaries based on the auxiliary tendency to form the thiolactone species with amide auxiliary 3.017 
and N-methyl-N-phenyl auxiliary 3.019 being especially prone to cyclization.  
Ethyl ester auxiliary 3.016 and N-phenylamide auxiliary 3.017, while not unsusceptible to 
cyclization, are less prone to form the thiolactone making these auxiliaries usable for ligation junctions 
of the X-Gly family and highly efficient at Gly-Gly junctions. This efficiency was demonstrated by 
synthesizing the full-length antimicrobial peptide DCD-1L. 
Advantages of auxiliary 3.016 include simple synthesis of the auxiliary precursor from 
commercially available and inexpensive starting materials and effective attachment onto a peptide 
directly on solid support contributing to the generality of the method by obsoleting the need to 
synthesize specific building blocks. 
The major achievement gained with these auxiliaries is the ability to cleave them from the 
ligation product under mild basic conditions. After optimization of the conditions needed for the 
removal, a mild and fast procedure for the cleavage of the auxiliary from the ligation product was 
successfully developed. As basic conditions were applied for removal of the auxiliaries, they should 
prove especially attractive when synthesis of proteins with acid sensitive posttranslational 
modification such as sulfonation or glycosylation are pursued. These advantages establish auxiliary 
3.016 as a legitimate and worthy addition to the existing ensemble of auxiliaries. 
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3.2 Synthesis of MUC1 Protein by Auxiliary-Assisted Solid Phase 
Chemical Ligation 
3.2.1 Concept and Introduction 
Seitz and coworkers recently reported a new class of highly potent Nα-auxiliary that has 
shown improved characteristics during ligation studies [95]. The 2-mercapto-2-phenylethyl auxiliary 
3.073 (scheme 3.16) can promote ligation at junctions past the Gly or Ala barrier. The precursor 
3.073* (scheme 3.16 A) is readily attached onto a resin bound peptide by reductive amination thanks 
to its aldehyde moiety, making it a universal tool for preparation of auxiliary modified peptides. 
Following ligation the auxiliary is selectively cleaved using mild conditions directly from the ligation 
mixture without intermediate purification thus reducing costly and lengthy purification steps.  
NCL continue to lead as the method of choice for synthesis of protein. Done in solution, it 
enables easy analysis of the reaction at every given time and can be directly purified as soon as the 
ligation is complete. Despite these advantages, attempts are constantly being made to apply ligation 
chemistry to solid phase. The motivation behind these trials is to exert the advantages SPPS gave the 
field of peptide synthesis and lend them to the field of total chemical synthesis of proteins. 
Despite progress in the field of SPCL, it still has not become a default method in the protein 
chemist’s toolbox. The reasons are compatibility issues of NCL and its extensions to the added 
requirements dictated by the polymer support, lack of a variety of suited polymer supports, and 
orthogonality problems between the reagents needed for the different stages (such as: anchoring and 
releasing of the peptides onto and off the support or protecting groups removal). 
The 2-mercapto-2-phenylethyl auxiliary 3.073 with its mild conditions for removal and ability 
to ligate broader range of junctions has the potential to make SPCL common practice. The use of 
commercially available Ni-NTA resin (Nickel Nitriloacetic acid), simplifies the setting of the 
reaction as the peptides are readily attached to the support (scheme 3.16B).  
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Scheme 3.16: Auxiliary assisted chemical ligation using auxiliary 3.73 in solution (A) and on solid 
support (B). 
3.2.2 The MUC1 Protein 
MUC1 is part of the mucin family proteins. These family of proteins is characterized by the 
presence of a mucin domain rich in proline, serine and threonine residues (PTS domain). The MUC1 is 
expressed in epithelial cells in mammals and serves many functions. It participates in numerous 
metabolic processes in the cell [122], provides protection against pathogens [123] as well as act as 
lubricant to protect the ephitelia [124]. It is a transmembrane protein consisting of three main domains 
(figure 3.23 A). The C-terminal consists of two domains: a cytoplasmic tail and a transmembrane part. 
The long extracellular PTS domain, also called variable tandem repeat (VNTR) makes up the N-
terminal of the protein. It is constructed of multiple repeats (ranging between 20-120 repeats) of 
identical 20 residues long peptide (PDTRPAPGSTAPPAHGVTSA). It is highly O-glycosylated at its 
numerous serine and threonine residues. The massive oligosaccharide construct is responsible for the 
protection of the cell by providing lubrication and physical barrier, preventing pathogens from 
reaching the cell surface.  
The MUC1 is overexpressed in most human epithelial cancers. The tumor-associated MUC1 
(TA-MUC1) differs from the normally expressed MUC1 (figure 3.23 B and C). Normal MUC1 is 
heavily glycosylated and localized at the apical surface of the cell. As cancer cells lack polarization 
and differentiation between different areas in the cell, TA-MUC1 is expressed all around the cell 
leading to over-expression. The TA-MUC1 is also hypo-glycosylated. These structural and spatial 
changes have been associated with increased endocytosis, and oncogenic signaling. The processes in 
which this happens are not completely clear. One theory is that the hypo-glycosylation unmasks the 
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peptide core thus allowing proteases to cleave the peptide extracellular domain which in turn causes 
conformational changes in the cytoplasmic tail, activating downstream cell signaling. 
 
Figure 3.23: A) MUC1 structure showing the different domains and their location; B) MUC1 
expression and distribution in healthy epithal cells; C) MUC1 expression and distribution in cancer 
epithal cells. 
The numerous roles MUC1 plays in cells and especially in cancerous cells make it imperative 
to understand and study its multifaceted mechanisms of action. The MUC1 is highly polymorphic in 
regards to the number of tandem repeats, the tandem repeat sequence variation as well as the 
glycosylation profile. All vary greatly between different tissues and cells. Obtaining homogenous 
samples of the peptide can be challenging. Chemical synthesis is a valuable tool for such complicated 
systems as it can produce homogenous samples of the protein with any desired modification. The 
MUC1 VNTR domain, with its multiple repeats, makes SPCL especially adequate for its synthesis, as 
the same “monomer” peptides can be sequentially added multiple times in a continuous, semi-
automatic process. 
3.2.3 Choice of Polymer Support 
Polymer support plays a key role in the successful utilization of SPCL. It must swell in 
aqueous mediums, allow easy attachment and release of the peptide fragments in an orthogonal 
fashion, and be stable to the reagents used in the ligation chemistry. Several polymeric materials have 
stood out as being compatible with these requirement. Most notably the PEGA resin has been 
successfully used for the synthesis of full length protein through the sequential SPCL of up to five 
peptide segments[94]. One of the limitations of the PEGA resin is to engineer the selective anchoring 
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of the unprotected peptide. Current methods require derivatization of the polymer and peptide to afford 
orthogonal binding. In order to avoid extra manipulation steps on peptides or resins to achieve 
orthogonal anchoring and release from the support, the commercially available Ni-NTA affinity resin 
was chosen[125]. It consists of beaded agarose derivatized with a nitrilotriacetic acid chelating moiety 
loaded with nickel ions (figure 3.24). The resin exhibits excellent swelling properties in aqueous 
medium. Adding a sequence of six histidine residues at the C- or N-termini of the peptide allows 
efficient and swift anchoring to the support. Detachment of the peptide from the support is also 
performed under mild conditions by suspending the resin in an aqueous buffer with high concentration 
of imidazole which competes with the His-Tag for binding the Ni(II)  
The Ni-NTA resin has long been used in the chemical and molecular biology fields for affinity 
chromatography of expressed proteins modified with a His6-Tag, taking advantage of the strong 
imidazole-nickel complex to selectively extract the desired protein from a cell lysate[126]. Kent et al. 
have used this resin for the non-chromatographic purification of ligation product[127]. 
 
Figure 3.24: Ni-NTA resin structure and coordination to histidine residues. 
3.2.4 Synthesis of Peptide Fragments for the C→N and N→C directed 
SPCL 
In NCL, which deals with the conjugation of two molecules, a concept of directional synthesis 
is irrelevant. Only if three or more peptide segments are needed to construct the full-length protein 
does direction come into play. SPCL, like SPPS or however, is always directional and performed 
either in C→N or N→C direction (scheme 3.17) depending on the peptide terminus that is attached to 
the solid support. To test the two options four peptides were synthesized: two auxiliary peptides and 
two thioester peptides with and without a His-Tag.  
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Scheme 3.17: Auxiliary-assisted SPCL of MUC1in C→N direction (A) and in N→C direction (B). 
Aux-MUC1-His6 3.079 was synthesized following Fmoc procedure. The auxiliary 3.073 was 
introduced by reductive amination. After 4 hr UPLC-MS analysis showed complete conversion to the 
desired auxiliary modified peptide Aux-MUC1(1-20)-His6 3.079. The peptide was cleaved from 
support by TFA treatment and purified by preparative HPLC to give the desired product in 40% 
isolated yield (figure 3.25). 
 
 
Figure 3.25: UPLC analysis of crude (A) and pure (B) Aux-MUC1(1-20)-His6 3.079; 03-60% B in 6 
min, 210 nm. 
As discussed previously, one of the goals of the project was to perform sequential SPCL. This 
requires a middle fragment containing the thiol and thioester functionalities. With this outlook in 
mind, peptide Aux-MUC1(1-20)-NH2 3.082 was instead synthesized as 3,4-diamino benzoic acid 
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(Dbz) derivative Aux-MUC1(1-20)-Dbz 3.086. The Dbz moiety functions as a latent thioester which 
can be activated post-ligation to function as thioester to allow elongation of the peptide chain (see 
section 3.2.8).  
Aux-MUC1-Dbz 3.086 was synthesized as described in literature for synthesis of Dbz 
peptides [128] (figure 3.26). Shortly, Fmoc-Gly-OH and Fmoc-Dbz-OH were manually coupled on a 
rink amide resin. The free amine group of the Dbz was protected as allyloxycarbamate (Alloc) and 
Fmoc was removed from the second amine. As the protection of one of the amines on the ring 
deactivates the neighboring amine, Fmoc-His(Trt)-OH was double coupled using HATU to ensure 
complete acylation of the amine. The rest of the sequence was synthesized by automated SPPS and the 
auxiliary 3.073 was introduced as described previously. The Alloc protecting group was removed by 
treatment with tetrakis(triphenylphosphine)palladium(0) and peptide was cleaved from support and 
protecting-groups removed with TFA:TIS:H2O cocktail. After preparative HPLC purification peptide 
was isolated in 30% yield. 
 
 
Figure 3.26: UPLC analysis of synthesis of Aux-MUC1(1-20)-Dbz-Gly 3.086. A) Crude H-MUC1(1-
20)-Dbz(Alloc)-Gly 3.089; B) Crude Aux-MUC1(1-20)-Dbz(Alloc)-Gly peptide 3.090; C) Pure Aux-
MUC1(1-20)-Dbz-Gly 3.086; 03-60% B in 6 min, 210 nm. 
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The thioesters peptides His6-MUC1(1-20)-SBzl 3.093 and H-MUC1(1-20)-SBzl 3.094 were 
synthesized using the safety-catch linker approach and isolated with 35% and 45% yield respectively 
(figure 3.27). 
 
 
 
 
Figure 3.27: UPLC analysis A) Pure His6-MUC1(1-20)-SBzl 3.093; B) Pure H-MUC1(1-40)-SBzl 
3.094; 03-60% B in 6 min, 210 nm. 
 
3.2.5 Attaching the peptides to the polymer support 
The His-Tagged peptides 3.079 and 3.093 were attached to a Ni-NTA resin pre-swelled in 
guanidinium phosphate buffer. After 1 hr full anchoring onto the resin was achieved (figure 3.28). The 
stability of the system to long exposure of thiols and TCEP was tested over three days (see p. 132) 
Results have shown the anchoring to the resin was not harmed with no peptide detected in the 
supernatant. 
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Figure 3.28: UPLC analysis of anchoring of peptides to the Nickel-NTA support. A) Auxiliary 
peptide 3.079; B) Thioester peptide 3.093; 03-60% B in 6 min, 210nm. 
 
3.2.6 Auxiliary Assisted SPCL on Ni-NTA Resin 
The ligation studies were carried out simultaneously on the two resin bound peptides 3.079 
and 3.093 by adding 1.1-1.2 equivalents of thioester 3.094 or auxiliary peptide 3.086 in ligation buffer 
containing 6 M Gn.HCl, 0.1 M NaH2PO4, 10 mM TCEP, 10 mM MPAA pH 7.2 and added to the 
resin. After 16 hr the resin was washed with buffer and water and the attached peptides released by 
suspending the resin in aqueous solution of 250 mM imidazole and 10 mM TCEP pH 8 for 30 min. 
The elution solution was collected and analyzed by UPLC-MS. Results demonstrated both directions 
to be equally effective producing a single peak corresponding to ligation product with crude purity of 
85% and 92% for peptide 3.095 and 3.096 respectively (figure 3.29). The two experiments have 
proven the compatibility of the Ni-NTA resin to SPCL application as well as the auxiliary capability to 
mediate ligation on solid support effectively and cleanly. 
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Figure 3.29: UPLC analysis of auxiliary assisted SPCL. A) N→C directed SPCL to give ligation 
product 3.095; B) C→N directed SPCL to give ligation product 3.096; 03-60% B in 6 min, 210 nm. 
 
3.2.7 Auxiliary Removal from ligation product 
Having proved the auxiliary’s ability to mediate ligation on solid support, removal of the 
auxiliary was tested. The resin bound ligation product His6-MUC1(1-20)-Aux-MUC1(1-20)-Dbz-Gly-
NH2 3.095 was released from support as described previously. To the elution buffer containing the 
peptide equal volume of auxiliary removal buffer (400 mM morpholine, 100 mM TCEP) was added 
and reaction was performed at 40 °C for 16 hr. 
As can be seen in figure 3.30 auxiliary removal was achieved but not completed. The 
incomplete removal is probably the result of the lower concentration of morpholine (200 mM) and 
TCEP (50 mM) combined with the slightly lower pH value due to dilution of the buffer with the 
imidazole solution. 
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Figure 3.30: UPLC analysis of auxiliary removal from ligation product 3.095 after 16 hr at 40 °C; 03-
60% B in 6 min, 210 nm. 
 
3.2.8 Efforts towards Sequential Auxiliary-Assisted SPCL 
With the successful initial studies of auxiliary-assisted SPCL in both C→N and N→C 
directions, the next goal was performing sequential SPCL using the auxiliary. This requires a synthesis 
of a middle fragment, having both thioester and auxiliary functionalities. To ensure selectivity one of 
the functional groups must be temporarily blocked (scheme 3.18). 
 
Scheme 3.18: General scheme for sequential auxiliary assisted SPCL in a N→C direction by using 
masked thioesters (A) and in a C→N direction relying on orthogonal protecting groups (B).  
In recent years, much effort was invested in the development of strategies for the synthesis of 
thioesters following Fmoc procedure. The methods mostly rely on introduction of a masked or latent 
thioester which is activated post-synthesis to yield a reactive thioester. The unmasking or activation of 
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the thioester is orthogonal to the synthesis and cleavage conditions used during SPPS and so should be 
compatible with unprotected peptide fragments. Three approaches were explored: The 3,4-
diaminobenzoic acid (Dbz) linker[128], kinetically controlled ligation (KCL)[129] and peptide 
hydrazides[130, 131]. 
3.2.8.1 Employing 3,4-Diaminobenzoic Acid as Masked Thioester 
The method was developed by Dawson for the synthesis of peptide thioesters by Fmoc 
strategy. The 3,4-diaminobenzoic acid is introduced in the beginning of the sequence and elongation 
of the peptide is done on one of the amines located on the benzene ring. Acylation of one of the 
amines deactivates the neighboring one and allows synthesis to be carried out without the need to 
protect the free benzylic amine. After SPPS is complete the protected Dbz 3.099 is cyclized to form 
the urea derivative 1H-benzo[d]imidazol-2(3H)-one (Nbz) 3.100, which possess thioester-like 
properties and can be substituted to form thioester 3.101 (scheme 3.19). The method was developed 
for protected peptides as having other free amines on the peptide backbone will lead to unwanted 
acylation. The MUC1 however, lacks lysine residues and thus only the Dbz amines should be available 
for acylation which should ensure selective acylation. Any acylation on other residues such as serine 
or threonine should form labile esters that can be hydrolyzed to retrieve the unmodified residue. 
 
Scheme 3.19: Synthesis of peptide thioesters employing Dbz 
Aux-MUC1(1-20)-Dbz 3.086 was ligated to resin bound His5-MUC1-SBzl peptide 3.102. 
After 16 hr UPLC-MS analysis showed full conversion to the ligation product 3.102 (figure 3.31 B). 
To form the thioester 3.104 the resin was suspended in DCM and treated with 4-
nitrobenzylchloroformate and DIEA. The resin was resuspended in ligation buffer for 10 min to 
promote thioester formation.  
During reaction the beads lost their characteristic blue colour and the texture of the resin 
changed which suggests modification of the resin’s hydroxyl groups. UPLC-MS analysis (figure 3.31 
C) revealed no product was formed. The major peak observed was ligation product His6-MUC1(1-20)-
Aux-MUC1(1-20)-Dbz-Gly 3.103. A secondary smaller peak with mass of +167 Da from desired 
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product 3.104 was also detected. This mass is most likely acylation of the N-terminal hexahistidine 
chain free amine. 
With negative results detected by UPLC as well as the beads incompatibility towards organic 
solvent the approach was abandoned. 
 
 
Figure 3.31: A) Thioester synthesis from Dbz; B) UPLC analysis of ligation product His6-MUC1(1-
20)-Aux-MUC1(1-20)-Dbz-Gly 3.103; C) UPLC analysis of thioesterification of ligation product 
3.103 to give thioester 3.104; peaks labelled with * correspond to unassigned masses; 03-60% B in 6 
min, 210nm. 
3.2.8.2 Employing Inactive Benzyl Thioesters for Controlled SPCL 
Ligation experiments done in solution have shown the auxiliary does not promote ligation 
when non aromatic thioesters are used. This characteristic of the auxiliary was utilized to try and 
perform kinetically controlled ligation (scheme 3.20). A benzyl thioester peptide 3.102 anchored to the 
solid support is activated by thiol exchange with an aromatic thiol (such as MPAA or thiophenol) to 
yield an active thioester 3.105. The active thioester is then ligated to a middle fragment 3.106 in 
absence of thiol additives, ensuring a selective reaction (figure 3.32) 
A 
D 
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Scheme 3.20: A) General concept of kinetically controlled ligation; B) Controlled auxiliary-assisted 
SPCL of MUC1. 
 
To form the active thioester the resin bound thioester His5-MUC1(1-20)-SBzl 3.102 was 
treated with a phosphate buffer containing guanidinium and either MPAA or thiophenol and reactions 
were monitored by UPLC-MS. In both experiments the major peak detected is the starting benzyl 
thioester with small peaks corresponding to hydrolyzed thioester (figure 3.32 B and C). 
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Figure 3.32: A) Scheme of transthioesterification of peptide 3.121 with different thiols; B-D) UPLC 
analysis of the reaction with MPAA (B), thiophenol (C) and MESNa (D). TE-OH: hydrolysed 
thioester peptide 3.102; Peak labelled with * is MPAA; Gradient B and D: 03-60% B in 4 min; 
Gradient C: 03-60% B in 6 min; 210 nm. 
 
A third experiment was performed using MESNa as thiol nucleophile. Being the most active 
aliphatic thioester [132] it should readily exchange the benzyl thioester and ideally be reactive enough 
to enable ligation with the auxiliary. Indeed, treating thioester 3.102 in a buffer containing MESNa 
resulted in full conversion to the MESA thioester 3.105c (figure 3.32 D). 
Next, ligation between the MESA thioester 3.105c and peptide Aux-MUC1(1-20)-SBzl 3.106 
in buffer containing 6 M Gn.HCl, 0.1 M NaH2PO4, 20 mM TCEP pH 7.2 was performed. 
Unfortunately MESA thioester proved to be not reactive enough to go through ligation with only 
starting material observed by UPLC analysis (figure 3.33). With no ligation taking place with MESA 
thioester and activation with more reactive aromatic thiols not proceeding the approach was 
terminated. 
A
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Figure 3.33: UPLC analysis of ligation between peptide 3.105c and 3.106 at A) 24 hr B) 48 hr; 03-
60% B in 4 min, 210 nm. 
 
3.2.8.3 Employing Peptide Hydrazides 
Similar to Dbz, peptide hydrazides also function as thioester precursors and can be 
transformed to thioesters. By treating the unprotected peptide hydrazides 3.108 with aqueous solution 
of sodium nitrite at slightly acidic pH, peptide azide 3.109 is formed. The azide in turn is being 
substituted to a thioester via a nucleophilic attack by a thiol (scheme 3.21). 
 
Scheme 3.21: General concept of thioester formation employing peptide hydsrazides. 
 
The peptide hydrazide was synthesized as described in the literature [130]. Chlorotrityl resin 
was treated with hydrazine in the presence of NEt3 in DMF to yield resin 3.110. The sequence was 
completed by automated SPPS. HPLC purification gave His6-MUC1-NHNH2 peptide 3.111 with 55% 
isolated yield (figure 3.34). 
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Figure 3.34: UPLC analysis of His6-MUC1(1-20)-NHNH2 3.111; Gradient: 03-60% B in 4 min; 210 
nm. 
 
The peptide 3.111 was anchored to the Ni-NTA Resin employing the previously described 
method and suspended in aqueous solution of 30 mM NaNO2 pH 3 at -10 °C for 30 min followed by 
addition of a phosphate buffer containing 20 mM MPAA pH 7.2 (final pH value is 6.8) at 25 °C for 30 
min. UPLC-MS analysis showed no reaction took place with a single peak corresponding to the 
hydrazide peptide 3.111 observed. Longer exposure times, increasing concentration of NaNO2 and 
MPAA or performing the two steps separately by first washing the resin from the nitrite buffer and 
then adding the MPAA containing buffer all did not change the result (figure 3.34 A). As the 
experiments in the previous section demonstrated thioesterification with MPAA is problematic the 
experiments were repeated using MESNa as thiol. Exchanging the thiol had no influence and no 
reaction was detected (figure 3.35 B). 
 
Figure 3.35: UPLC analysis of peptide hydrazide 3.111 transformation to thioester. 3.105. A) with 
MPAA; B) with MESNa; 03-60% B in 4 min, 210nm. 
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As control, the reaction was performed in solution using the same conditions. In the control 
experiment thioester formation was detected (figure 3.36) meaning that the problem does not lie with 
the system itself but rather stems from some kind of hindrance presented by the solid-phase. Without 
being able to form the thioester the route was abandoned as well. 
 
Figure 3.36: UPLC analysis of peptide hydrazide 3.111 transformation to thioester. 3.105a; TE-OH: 
hydrolysis of thioester 3.100; Peak labelled with * correspond to unassigned masses; 03-60% B in 4 
min, 210nm. 
 
3.2.8.4 Efforts toward Sequential Ligations: Summary 
In this section an attempt to perform sequential ligation on solid support was made. Utilizing 
latent thioester or thioester precursors to achieve selective ligation between two peptide fragments for 
the selective chemical ligation between a thioester H-MUC1(1-20)-SR and a middle fragment Aux-
MUC1(1-20)-X (X is an inactive crypto thioester or low reactive thioester). Three approaches were 
tested: The N-acyl urea approach, formation of highly active thioesters pre-ligation and performing 
KCL and in-situ conversion of peptide hydrazide into peptide thioester.  
In the first case, a peptide was synthesized on a Dbz linker to give the Aux-MUC1(1-20)-Dbz-
Gly 3.085. The peptide was successfully ligated to a resin anchored His6-MUC1(1-20)-SBzl 3.093 
under standard ligation conditions to yield peptide His6-MUC1(1-20)-Aux-MUC1(1-20)-Dbz-Gly 
3.095. Activation of the Dbz moiety to the active Nbz species was tried following the known protocol 
[128] which is done in organic medium of DMF and DCM. These conditions proved incompatible 
with the resin leading to its decomposition.  
Use of differently active thioester peptides to perform KCL was tried next. By forming an 
active aryl thioester prior to adding the middle fragment and performing ligation in absence of thiol 
additive a selective ligation will take place leading to formation of a single ligation product. Peptide 
thioester His6-MUC1(1-20)-SBzl 3.093 was anchored to Ni-NTA resin and treated with aqueous 
buffer containing MPAA, thiophenol or MESNa. Treatment with MPAA or thiophenol did not yield 
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the desired respective thioesters His6-MUC1(1-20)-MPAA 3.105a or His6-MUC1(1-20)-SPh 3.105b 
and starting benzyl thioester 3.093 remained as major species. Conversion to the MESA thioester 
3.105c was quantitative however, the thioester proved too unreactive to participate in the ligation and 
no product was detected. While in-situ formation of MPAA or thiophenol thioesters in the presence of 
a cysteinyl or cysteinyl equivalent peptide is possible, as the active thioester is immediately attacked 
by the cysteinyl peptide to forms the stable thioester or amide bond, isolation of such active thioesters 
is challenging due to the very high reactivity of such species. Similar results were encountered on 
other occasions when attempts to prepare MPAA thioesters in solution by transthioesterification 
reached a conversion lower than 50% despite using high excess of reactants or prolonging the 
reactions time.  
Peptide hydrazides have previously been used as masked thioesters [133-135]. Classic 
procedure to convert these species into active thioesters required protection of other amine and thiols 
on the sequence and working in organic solvents. Recently, Liu et al. have developed a new procedure 
that allows peptide thioesters to be formed in-situ from peptide hydrazides [130] and have also 
demonstrated the peptide hydrazide utility in KCL [131]. While conversion to the thioesters proceeded 
well in solution, the peptide hydrazide was completely inert once anchored to the Ni resin. The reason 
behind the hydrazide inertness is the strong affinity of the hydrazide moiety towards the Ni(II) ions 
[136] Similar to the imidazole, the hydrazine moiety forms a highly stable complex with the Nickel 
which renders it unavailable and completely hinders the reaction.  
 
3.2.9 Auxiliary-Assisted SPCL of a 80mer VNTR MUC1 Peptide 
The experiments on the nickel solid support have shown that the support is applicable for the 
ligation chemistry being water swellable and stable towards the reagents used in ligation. Although 
attempts to perform sequential ligation from the N→C direction did not yield a positive result, 
ligations of two fragments were easily accessible. The MUC1 synthesis has also been optimized 
throughout the experiments reaching highly effective synthesis with good yields and minimum 
truncation sequences. Through this optimization process, the 40mer MUC1 peptide, consisting of two 
tandem repeat sequence, was synthesized as well. As a final goal and proof of applicability of the 
auxiliary assisted SPCL, the 80 amino acids long MUC1 VNTR peptide was to be synthesized 
employing a single ligation step. Ligation of longer peptide fragments is often slower and leads to a 
larger amount of side products due to incomplete ligation. It is in cases such as these where the solid 
support internal purification characteristic makes it an especially attractive technique. As any excess 
reagents and unreacted reactants can be washed off the resin, it should give a clean ligation profile and 
easy isolation of the product.  
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3.2.9.1 Synthesis of Fragments MUC1(1-40)-SBzl 3.112 and Aux-MUC1(41-80)-His6 
3.114 
The 40mer benzyl thioester MUC1(1-40)-SBzl 3.112 was synthesized as described in the 
previous section employing the safety catch linker. After purification on a preparative HPLC thioester 
3.112 was isolated with 35% yield (figure 3.37). 
Figure 3.37: UPLC analysis of crude (A) and pure (B) H-MUC1(1-40)-SBzl thioester peptide 3.112; 
03-60% B in 6 min, 210 nm.
The auxiliary peptide Aux-MUC1(41-80)-His6 3.114 was synthesized following standard 
SPPS procedure. After synthesis was complete the auxiliary was attached to the peptide using 
reductive amination. The peptides were cleaved and purified on preparative HPLC to yield the pure 
peptides with 15% yield (figure 3.38). 
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Figure 3.38: UPLC of Aux-MUC1(1-40)-His6 3.113. A) Crude H-MUC1(1-40)-His6 X; B) Pure 
peptide Aux-MUC1(1-40)-His6 3.114; 03-60% B in 6 min, 210 nm. 
 
3.2.9.2 Auxiliary Assisted SPCL towards MUC1(1-80) VNTR 
With the two peptide fragments isolated, auxiliary-assisted SPCL was performed as follows: 
auxiliary peptide 3.114 was anchored to the nickel support as previously described. Complete 
attachment was observed after 1.5 hr. The resin was washed and the thioester peptide 3.112 (1.2 eq), 
dissolved in a buffer of 6 M Gn.HCl, 0.1 M NaH2PO4, 10 mM TCEP, 20 mM MPAA, pH 7.5, was 
added to resin. The reaction was performed at 25 °C and monitored by UPLC-MS. A fresh batch of 
thioester 3.112 (0.5 eq) was added in 24 hr intervals. The process was repeated two times after which 
complete conversion to the desired ligation product 115 was detected by UPLC-MS analysis (figure 
3.39). 
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Figure 3.39: UPLC analysis of SPCL between H-MUC1(1-40)-SBzl 3.112 and Aux-MUC1(1-40)-
His6 3.114 to give ligation product 3.115 at A) 0 hr; B) 24 hr; C) 72 hr; 03-60% B in 6 min, 210 nm. 
3.2.9.3 Removal of Auxiliary from Ligation Product MUC1(1-80) VNTR 
In order to remove the auxiliary 20 µl of an aqueous buffer containing 4 M morpholine and 1 
M TCEP (pH 8.5) was added to 20 µl elution solution containing the released ligation product 3.115 
for 16 hr at 25 °C (figure 3.40). The product was directly isolated by semi-preparative HPLC to yield 
the desired H-MUC1(1-80)-His6 3.116 in 45% yield (figure 3.40). 
Figure 3.40: UPLC analysis of removal of auxiliary from crude ligation product 3.115 to give H-
MUC1(1-80)-His6 3.116; A) 0 hr; B) 16 hr; C) Purified H-MUC1(1-80)-His6 3.116; 03-60%B in 6 
min, 210nm. 
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3.2.10 Auxiliary-mediated SPCL Conclusions 
To date, most proteins and peptides synthesized by NCL and its numerous extensions are 
synthesized in solution. Working in solution allows the reaction to be directly and swiftly set up, easily 
analyzed and purified without the need for work-up step. Solution phase NCL is indispensable and 
advancements in performing multiple ligations sequentially are constantly being made. Despite the big 
leaps the field has gone through, sequential NCL is still limited. Incompatible reagents prevent 
continuation of the protein chain, thiol additives prevent desulfurization, protecting groups such as 
acetamidomethyl (Acm) require different medium for removal, or unmasking of thioesters becomes 
incompatible with other functional groups. Furthermore, ligation of several fragments leads to 
accumulation of side products and unreacted reactants. 
As the field of chemical synthesis matures and the complexity of desired targets increases 
attempts are continuing ever more often to adapt NCL to be performed on solid phase. The motivation 
behind these trials is to exert the advantages SPPS gave the field of peptide synthesis and lend them to 
the field of total chemical synthesis of proteins, i.e. ability to use large excess of reactants to force the 
ligation to completion, performing consecutive reaction in one-pot, easy removal of side-product and 
excess reagents by simple washing steps and the possibility to automatize the process. SPCL has 
proven itself as a very powerful tool for sequential ligation. In this work, efforts towards the first 
auxiliary mediated SPCL has been taken and successfully achieved.  
Appropriate solid-support was found in the form of the His-Tag affinity resin. It has excellent 
swelling properties in aqueous buffers, it is durable against thiols and phosphines and provides 
orthogonal anchoring and release of the peptides onto and from the support.  
The auxiliary presented in this work has allowed the first successful auxiliary-mediated SPCL. 
Ligations of peptides fragments 20 residues in length were complete within 15 hr with exceptional 
purity. Ligation of 40mer fragments, which are often slow even when performed in solution, were 
successful as well, reaching completion in 3 days thus further highlighting the usefulness and usage of 
this new auxiliary.  
The ability to remove excess reagents and reactants by washing allowed high equivalents of 
thioester to be introduced while avoiding troublesome purification. The mild conditions required to 
release the peptides from support proved compatible with the conditions required for removal of the 
auxiliary, further minimizing purification steps and allowing the entire synthesis to proceed as a 
continuous process. 
To summarize, the first auxiliary assisted SPCL was demonstrated utilizing the newly conceived 
2-mercapto-2-phenylethyl auxiliary 3.073. The auxiliary was effectively and rapidly coupled to the 
peptide directly during SPPS and promoted SPCL at peptide fragments of various lengths effectively 
and cleanly. The mild removal chemistry of the auxiliary as well as the mild release of the product 
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from the solid support makes the method ideal for synthesis of peptides with acid sensitive post 
translational modification such as phosphorylation, sulfonation or glycosylation. 
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4 Summary and Outlook 
4.1 Summary 
Nα-auxiliaries for assisting NCL have been a topic for research since very early on after 
the introduction of NCL. With the potential to resolve the requirement for a cysteine residue at the 
ligation site, which continues to be the major limitation of NCL, and potentially allow ligation to 
be performed in a variety of junctions, they stood in the center of several researches. Despite 
advancements and progress taken in the field over the years, the auxiliaries have yet to fulfill their 
full potential, mostly due to inability to assist ligation at difficult junctions. In this study, the 
scope of auxiliary assisted NCL was extended. A novel family of Nα-auxiliaries was designed, 
developed and utilized for the synthesis of peptides and proteins. The auxiliaries aided the 
chemoselective condensation of peptide fragments to form full-length peptides and proteins of 
different length in targets unattainable by conventional NCL thus extending the chemists available 
tools for synthesis of proteins. In the first part of the dissertation a group of auxiliaries were 
designed to be labile towards mildly basic conditions by abstraction of an acidic proton located on 
the auxiliary, leading to cleavage from the peptide via an elimination mechanism. Four 
auxiliaries, based on 4-mercaptobutyrate scaffold, were synthesized, each featuring a different 
electron withdrawing group. The auxiliaries were studied for their ability to mediate native 
chemical ligation (scheme 4.1).  
Scheme 4.1: Structure and proposed mechanism of auxiliary-assisted NCL and base induced 
cleavage of auxiliaries to yield the native peptide bond. 
The auxiliary peptides were assembled directly on the solid support by reductive 
amination between the N-terminal amine of the peptide and a ketone function located on the 
auxiliary precursor backbone. This synthetic route gives universality to the method as the 
auxiliaries can be coupled to any peptide without the need to synthesize modified amino acid 
building blocks for different ligation junctions (scheme 4.1). 
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Table 4.1: Yields of auxiliary peptides 3.42-3.49. 
Auxiliary 
Peptide 
Isolated yield Auxiliary Peptide Isolated yield 
3.042 30% 3.046 36% 
3.043 14% 3.047 15% 
3.044 24% 3.048 16% 
3.045 18% 3.049 15% 
The efficiency of the four auxiliaries in mediating ligation was tested in model studies at 
four junctions, each with increasing sterical demand: Gly-Gly, Ala-Gly, Gly-Ala and Ala-Ala. 
Product formation over time for each of the auxiliaries is shown in figure 4.1. The data clearly 
shows that ligation is highly effective at Gly-Gly junction but efficiency quickly drops with 
increase in sterical demand. Ala-Ala junction draws the limit of the auxiliaries’ ability to mediate 
ligation, with no ligation product formed.  
Figure 4.1: Product formation over time of the four auxiliaries at different ligation junction. 
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Figure 4.2: UPLC analysis of measurements at 0 hr of ligations between thioester 3.052 and 
auxiliary peptides 3.042 (A), 3.044  (B), 3.46  (C) and 3.048  (D) demonstrating auxiliaries’ 
tendency to form the thiolactone species 3.050; 03-60% B in 6 min, 210 nm. 
Between the four auxiliaries, it was the ethyl ester auxiliary 3.016 and N-phenylamide 
auxiliary 3.018 that have shown the best results while the amide auxiliary 3.017 and N-methyl-N-
phenyl auxiliary 3.019 gave poor results throughout the entire study. The large difference between 
the auxiliaries does not stem solely from the differences in the auxiliaries’ rate constants which 
only differ slightly from one auxiliary to the next, but from a second property all the auxiliaries 
possess: formation of a 5- membered thiolactone ring via cyclization. Once in this structure, the 
auxiliaries cannot mediate the ligation as the thiol moiety is no longer available. The thiolactone 
form itself is highly susceptible and is swiftly being removed from the peptide backbone to yield 
the free amine peptides GRAEYSGLG 3.032 or ARAEYSGLG 3.033 as seen when peptide 
thiolactone 3.050 was dissolved in ligation buffer to yield the unmodified peptide 3.032 within 2 
hr (figure 3.6 B). 
Despite differences in the tendency to form the thiolactone, all auxiliaries formed it over 
time. In ligation sites with increased sterical hindrance, when the auxiliary assisted ligation could 
not proceed (as is the case for the Ala-Ala junction), the formation of the thiolactone and its 
consequential removal to give peptides 3.032 or 3.033 became the major path (figure 4.3). 
The removal of the thiolactone species under ligation condition was only observed on the 
auxiliary peptide. Once ligation product forms no removal of auxiliary was detected. This 
behavior seems to contradict known principles about leaving group tendency. Amides are much 
better leaving groups than amines due to the stabilization of the nitrogen lone-pair electrons along 
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the amide bond, reducing their basicity. This opposite behavior of the system hints towards 
auxiliary removal via a radical pathway.  
Figure 4.3: UPLC analysis of ethyl ester auxiliary assisted NCL at Ala-Ala junction at 0 and 24 
hr; 21: Aux-ARAEYSGLG, 31: LYRAA-SR, 11: ARAEYSGLG, TE-OH: LYRAA-OH; 03-60% 
B in 6 min, 210 nm. 
The results of the model studies showed only ethyl ester auxiliary 3.016 and N-
phenylamide auxiliary 3.018 were stable enough to be used in auxiliary-assisted NCL. As ethyl 
ester auxiliary 3.016 shown better results and is more readily synthesized, the three other 
auxiliaries 3.017, 3.018, and 3.019 were discarded from further experiments. 
To cleave the auxiliary from ligation product aqueous buffer containing TCEP and one of 
the bases: NaOH, morpholine, piperidine or EDMA were tested. Between the four bases only 
morpholine and piperidine have cleaved the auxiliary and gave the native, unmodified ligation 
product (figure 4.4A). Examining the efficiency of the two bases showed that the more basic 
piperidine was more potent but produced more unidentified impurities. Morpholine produced a 
cleaner reaction with fewer side products while still exhibiting satisfactory removal rates (figure 
4.4B and C). 
With experimental data validating the applicability and the initial theorem of the base 
labile auxiliary on short model peptides, a more challenging target was chosen to test the auxiliary 
ability to promote ligation on complex, biological relevant systems.  
As a target the antimicrobial peptide DCD-1L was chosen. The 48 residues long peptide 
was split into two fragments with ligation site at Gly-Gly. After 7 hr full conversion to ligation 
95 
product was detected. Ligation product was purified by semi-preparative HPLC in 50% yield. The 
pure peptide was subjected to removal buffer for 6 hr to give the native DCD-1L peptide isolated 
in 40% yield (figure 4.5). 
Figure 4.4: UPLC analysis of removal of auxiliary from ligation product 3.054 to give native 
peptide 3.068 after 5 hr. A) Screening of base component;  B) Piperidine treatment at 50 °C and 
60 °C; C) Morpholine treatment at 50 °C and 60 °C; 03-60% B in 6 min, 210 nm. 
Figure 4.5: Synthesis of DCD-1L. A) Scheme depicting synthetic route; B) UPLC analysis of 
ligation between Der1 and Der2 and auxiliary removal to yield native DCD-1L; C) MS analysis 
Der12 with observed mass 4963.6 Da (calc. 4963.7 Da); 03-70% B in 6 min, 210 nm. 
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In the second part of the work, a different class of Nα-auxiliary, 2-mercapto-2-
phenylethyl, developed by Loibl et al. [95] was applied for auxiliary assisted solid phase chemical 
ligation for synthesis of MUC1 tandem repeat domain. In comparison to the previous auxiliaries 
the auxiliary exhibits better reactivity under reductive amination condition thanks to an aldehyde 
functionality instead of a ketone, complete stability under ligation conditions and ability to 
mediate ligation in a wide range of sites (scheme 4.2). 
Scheme 4.2: General concept for synthesis of auxiliary peptides, ligation and auxiliary removal. 
The auxiliary assisted SPCL was performed on water swellable His-Tag resin to enable 
easy, mild and orthogonal binding and release of the peptide fragments onto- and off the resin. 
The ligations were tested in both C→N and N→C directions with both directions giving excellent 
results. The ligation product was released from support by imidazole treatment and auxiliary was 
removed in one-pot by adding the removal buffer (figure 4.6). 
Figure 4.6: UPLC analysis of auxiliary assisted SPCL. A) N→C directed; B) C→N directed; 03-
60% B in 6 min, 210 nm. 
97 
Efforts towards sequential SPCL were taken as well. Concentrating on N→C directed 
ligation, three strategies relying on employing masked or hindered thioesters were tested (scheme 
4.3): 3,4-diaminobenzoic acid (Dbz) linker used in Fmoc synthesis of thioesters is activated post 
synthesis by cyclization to form the urea derivative which can be substituted to give a thioester. 
The method proved incompatible with the polymer support that does not tolerate organic solvents 
that are required to activate the precursor. A second approach involved peptide hydrazides. These 
are synthesized in a straightforward manner via Fmoc SPPS and are later transformed into peptide 
azides which in turn form the thioester in presence of thiols. Experiments in solution proved 
successful with formation of thioester detected. When tried on a resin bound peptide however, the 
hydrazine peptides were completely inert to the treatment with no product formed. A third 
approach took advantage of the auxiliary inability to mediate ligation with benzylic thioesters to 
perform kinetically controlled ligation. The benzyl thioester MUC1, anchored to the His-Tag 
resin, was treated with a buffer containing MPAA, thiophenol or MESNa. MPAA and thiophenol 
did not produce the desired thioester. Treatment with a buffer containing MESNa, a full 
conversion was observed. However, the MESNa thioester proved not reactive enough to react 
with the auxiliary peptide, failing to produce the ligation product. 
Scheme 4.3: Strategies for activation of masked thioesters..A) Using Dbz linker; B) Using peptide 
hydrazides; C) Using KCL. 
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Finally the applicability of the method was tested for ligating long peptides fragments by 
synthesizing a 80mer MUC1 VNTR domain peptide. The reaction was successful, demonstrating 
the auxiliary applicability to mediate ligation of long peptides. The ligation proved more 
challenging than the previous shorter fragment condensation, taking 3 days to complete and 
requiring addition of thioester peptide to be driven to completion. In cases such as these the 
advantage of solid support chemistry come into play, as the excess thioester, which would 
normally remain in solution and often complicates purification, was washed off the support 
contributing to high crude purity. As before, the auxiliary was removed in-situ to give the native 
MUC1 peptide (figure 4.7). 
Figure 4.7: UPLC analysis of synthesis of 80mer MUC1 VNTR peptide 3.116; 03-60% B in 6 
min, 210 nm. 
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4.2 Outlook
This work has continued previous efforts to develop a new type of auxiliaries for 
extending native chemical ligation at cysteine free junctions [96]. Unlike the existing auxiliaries 
for NCL which are based on protecting group derivatives and are removed under acidic 
conditions, the new auxiliaries are based on an aliphatic flexible scaffold. Their removal 
chemistry was completely revamped to proceed under mild basic conditions. These changes were 
envisioned to allow these auxiliaries to overcome the problems encountered by the existing array 
of auxiliaries. The main features for optimization refer to expanding the scope of available 
ligation junctions and development of auxiliary removal conditions that are compatible with 
sensitive peptide moieties and modifications.  
From observations made in this work several modifications to the system could be 
incorporated to improve the auxiliaries’ usability. Results have shown that the β-branched 
substituted amine prevented ligation at sterically demanded junctions to proceed. Redesigning the 
auxiliary to produce a sterically less-demanding secondary amine will serve two purposes: more 
effective coupling of the auxiliary to the peptide and allow ligation of peptide fragments beyond 
the Ala-Gly and Gly-Ala junctions. A redesign of the scaffold could also prevent the undesired 
thiolactonisation, thus eliminating the auxiliaries’ premature removal. The auxiliaries’ removal 
chemistry, based on a mild basic treatment should theoretically prove compatible with common 
sensitive modifications of proteins. Here too, optimization of the EWG and removal conditions 
could improve the removal rate and selectiveness.  
The results gained in the first part of the study have also led to the design of a “second-
generation” auxiliary with highly improved properties in key factors, mainly: a more efficient 
attachment to the peptide and broader number of accessible ligation junctions. The auxiliary has 
also proven to be efficient in solid phase chemical ligation in a variety of peptides lengths, giving 
access to highly pure products. Further improvements and modification of the auxiliary such as 
derivatization of the phenyl ring with electron donating groups should improve the rate of ligation 
in sterically hindered junctions as well as allowing faster, more selective and more efficient 
removal of the auxiliary to achieve the native protein. 
Despite difficulties in performing sequential SPCL, it is not an inherent problem but 
rather a question of utilizing the appropriate method. Other latent thioesters than the one tested 
could be used, such as thiocarboxylates [92], SEA linker [93] or system based on a N→S or O→S 
acyl shift [85, 88, 90, 137-139]. Alternatively, orthogonal thiol protecting groups like thiazolidine 
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or 2-(methylsulfonyl)ethyl carbonate could be utilized to perform sequential ligations in the C→N 
direction.  
A possible application for auxiliary assisted SPCL could take advantage of the inherited 
purification characteristic of solid phase reactions. By performing the ligation in the N→C 
direction, a double purification process could be achieved without the need for HPLC 
purification. First, the crude His-tagged thioester could be anchored on the solid support. All 
truncation could be washed off the support leaving only the full length tagged peptide anchored 
(one must take care that no truncations in the His-Tag chain occurs which can be done for 
example by employing the “thioester with self-purification” method [140]). The crude auxiliary 
peptide could be directly ligated as all truncated fragments will lack the auxiliary moiety and will 
be washed off the support leaving the pure ligation product as a single species. 
The initial demonstration of the auxiliary SPCL capabilities should open a door to 
synthesis of longer and more complex proteins of interest by sequential SPCL with high purity 
and yield, hopefully turning auxiliary-assisted NCL wide-spread and useful addition to the toolkit 
of scientist working at the edge of biology and chemistry. 
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5 Experimental Part 
5.1 Instruments and Materials 
Chemicals and Instruments Specifications: Commercially available compounds were used 
without further purification. Dry solvents were taken from a Braun solvent purification system 
SPS 800. Purification of compounds by flash chromatography was done on silica gel (0.060-0.2 
mm, 60 Å) from Acros Organics using technical grade solvents. TLC silica gel plates 60 F254 from 
Merck were used for thin-layer chromatography. NMR-spectra were recorded on a Bruker Avance 
II 500 MHz spectrometer and referenced to the residual protonated solvent signal. HRMS-spectra 
were recorded on a QstarXL spectrometer from Applied Biosystems. 
SPPS: Solid-phase chemistry was carried out in syringes, equipped with teflon filters, purchased 
from Torviq or using peptide synthesizer (CS Bio Co. CS336x). If not described differently, all 
reactions were carried out at room temperature. DMF was purchased in biotech grade. Peptide 
Commercial reagents were used without further purification. Resins, protected amino acids and 
activating agents were purchased from Novabiochem. 
UPLC-MS measurements were performed on an Acquity UPLC system from Waters using a 
BEH130 C18 column (130 Å, 1.7 µm, 2.1 x 50 mm; heater set on 50 °C) with a binary mixture of 
A (0.1 % TFA, 1 % acetonitrile, 98.9 % H2O) and B (0.1 % TFA, 1 % H2O, 98.9 % acetonitrile) 
as a mobile phase (flow = 0.5 mL/min) in a linear gradient as described. 
HPLC-MS measurements were performed on an 1100 Series system from Agilent using a Polaris 
C18 column (3 µm, 2 X 100 mm; heater set on 50 °C) from Varian with a binary mixture of A 
(0.1 % formic acid, 1 % acetonitrile, 98.9 % H2O) and B (0.1 % formic acid, 1 % H2O, 98.9 % 
acetonitrile) as a mobile phase (flow = 0.3 mL/min) in a linear gradient as described. 
Preparative HPLC purifications were carried out on a 1100 Series system from Agilent using a 
Nucleodur C18 Gravity (5 µm, 250 mm) from Macherey-Nagel with a binary mixture of A (0.1 % 
TFA, 1 % acetonitrile, 98.9 % H2O) and B (0.1 % formic acid, 1 % H2O, 98.9 % acetonitrile) as a 
mobile phase (flow = 15 mL/min) in a linear gradient as described. For semi-preparative HPLC-
purifications a Polaris C18-A (5 µm, 250 x 10.0 mm) from Varian was used with a binary mixture 
of A (0.1 % TFA, 1 % acetonitrile, 98.9 % H2O) and B (0.1 % TFA, 1 % H2O, 98.9 % 
acetonitrile) as a mobile phase (flow = 6.0 mL/min) in a linear gradient as described. 
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Concentrations of peptide solutions were determined by using the absorption at 278 nm 
measured with ND-1000 spectrophotometer from Peqlab Biotechnology GmbH. The extinction 
coefficients of the peptides were calculated as the sum of the extinction coefficients of the 
tyrosine and tryptophane residues: 
ε278(Tyr) = 1400 L/(mol · cm) 
ε278(Trp) = 5600 L/(mol · cm) 
Coupling Efficiency Determination: Fmoc group is removed as described before. The combined 
piperidine washes (1 ml) are united. 20% piperidine in DMF (900 µl) in a UV cuvette is placed in 
a spectrophotometer and blank is measured at λ=301 nm. 100 μl of the Fmoc cleavage solution is 
added to the cuvette, mixed and the absorbance is measured at 301 nm. Coupling is calculated 
using the equation: n (    ) = 
                               (  )
     (  )  (       )
  
 
5.2 General Methods 
Manual SPPS by Fmoc Strategy: Amino acid, HCTU and HOBt (4 eq. each) and NMM (8 eq.) 
were dissolved in DMF (final concentration 0.4 M) and transferred to the resin. After 30 min, the 
resin was washed with DMF (X5) and unreacted sites were capped by treating the resin with 1 ml 
solution of 5 % Ac2O and 6 % 2,6-lutidine in DMF (1:2:1 min). Resin was washed with DMF 
(X5). Fmoc Group was cleaved by treating the resin with 1 ml solution of 20% piperidine in DMF 
(3:7:3 min). 
 
Synthesis of Thioesters by Boc Strategy: MBHA resin (0.59 mmol/g) was washed with DMF 
(X3) and treated with 10% DIEA/DMF for 10 min and additional wash with DMF (X3). Fmoc-
Gly-OH (4 eq) was coupled on a HMBA resin using HBTU and HOBt (4 eq. each) and NMM (8 
eq.) in DMF (final concentration 0.4 M). Fmoc was removed by treating the resin with 1 ml 
solution of 20% piperidine in DMF (3:7:3 min) and loading was determined. 3-(tritylthio) 
propanoic acid (4 eq) was pre-activated with HBTU (4eq) and DIEA (8 eq) in DMF (final 
concentration 0.4 M) for 5 min and added to the resin. After 1 hr the resin was washed with DMF 
(X3). The trityl protecting group was removed using a mixture of TFA:TIS:water (90:5:5 v/v). 
The in situ neutralization protocol developed by Kent and coworkers was applied for peptide 
assembly [141]. 
Boc deprotection: The resin was washed with DCM (X5) and treated with 1 ml solution of 5% m-
cresol in TFA (1:2:1 min). Resin is washed with DCM(X5) then DMF (X5). 
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Cleavage: A mixture of TFMSA:TFA:thioanisole (2:8:1, v/v) was added to the resin. After 1.5 h, 
the resin was washed with TFA (4 x 4 mL).  
Work-up: The combined solutions were concentrated in vacuum. The residue was dissolved in 
water, purified by preparative HPLC and analyzed by HPLC-MS. 
Automated SPPS: The reaction vessel containing the preloaded resin was placed in an automated 
peptide synthesizer.  
Coupling:           Amino acid, HCTU, OxymaPure (4 eq. each) and NMM (8 eq.) are mixed 
together 
   in DMF (final concentration 0.4 M) and transferred to the resin. 
       Coupling times:  Residues 1-10 1X 30 min; Residues 11-24 2X30 min; 
Residues  
25-End 3X30 min.
   Between couplings the resin was washed with DMF (3X500 µl). 
Capping:             A mixture of 5 % Ac2O and 6 % 2,6-lutidine in DMF (400 μl) was added to the 
resin  
  for 5 min. 
Fmoc deprotection: Resin was treated with 500 μl 20% piperidine in DMF. 
  Deprotection times:  Residues 1-10 5:5 min; Residues 11-End 5:8 min.  
After last cycle the resin is capped and washed with DMF (X3) and DCM (X3) and dried under 
vacuum. 
Thioester Synthesis using Safety-Catch Linker Strategy:  
Loading: 4-sulfamylbutyryl resin (5 eq.) swelled in chloroform.  Amino Acid, PyBOP (1 eq.) and 
DIEA (3 eq.) dissolved in CHCl3 (final concentration 0.25-0.3 M) and added to 
resin. The resin is shaken at -20 °C for 2 hr then washed with CHCl3 and swelled 
in DMF.  
Loading determination:  Performed by monitoring loading efficiency as described below. 
Rest of synthesis is continued on the automatic peptide synthesizer as described above. 
Changing the N-termini protecting group: Fmoc is removed as described in the general protocol 
and  
coupling efficiency is checked as described below. Boc2O and DIEA (50 eq. each 
) in enough DMF to cover the resin is added and shaken at rt for 30 min then 
washed with DMF and DCM. 
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Activation of sulfonamide linker: Resin swelled in dry THF. Trimethylsilyldiazomethane (2 M in 
hexane) (50 eq. from original loading) is diluted with dry THF 1:1v/v and added 
to resin at rt for 2 hr. Resin washed with THF and DCM.  
Thiolysis and release from resin: Resin swelled in DMF. Benzyl mercaptan (50 eq. from original 
loading) and sodium thiophenolate (1 eq. from original loading) in dry DMF are 
added to resin. Resin is shaken at rt 16 hr. The solution is transferred into a falcon 
tube and resin is washed thoroughly with DMF (X5) and DCM (X5). The 
combined washes are added to the falcon tube and solution is evaporated to 
dryness under vacuum. 
Cleavage of protecting groups and isolation of peptide: Performed as described below under the 
    general procedure for Fmoc SPPS cleavage and purification of peptides. 
Thioester synthesis using N-Acylurea Strategy:  
Preparing the Dbz modified resin: Rink amide resin (0.19 mmol/g, 0.05 mmol scale) was swelled 
in  
DMF. Fmoc-Gly-OH (0.2 mmol, 4 eq) and Fmoc-3,4-diaminobenzoic acid (0.2 
mmol, 4 eq) were double coupled for 1 hr. Resin is capped as described above. 
Alloc protection: The resin is swelled in DCM allylchloroformate (5 mmol, 100 eq) and DIEA 
(0.05 mmol, 1eq) in dry DCM are added to the resin for 14 hr. Resin is washed 
with DCM and DMF and capped. 
Loading of first amino acid: Fmoc-His(Trt)-OH (0.2 mmol, 4 eq), HATU (0.2 mmol, 4eq) and 
NMM (0.4 mmol, 8 eq) are dissolved in DMF and added to resin for 2 X 1 hr. 
Rest of synthesis is continued on the automatic peptide synthesizer as described above. 
Changing the N-termini protecting group: Fmoc is removed as described in the general protocol 
and  
coupling efficiency is checked as described below. Boc2O and DIEA (50 eq. each 
) in enough DMF to cover the resin is added and shaken at rt for 30 min then 
washed with DMF and DCM. 
Alloc Deprotection: Resin is swelled in dry DCM and Pd(PPh3)4 (0.15 mmol, 3 eq) in 92.5:5:2.5 
v/v  
DCM:AcOH:NMM is added to resin and shaken 2 hr at rt. Resin is washed with 
DCM, DMF, 0.5% v/v DIEA/DMF, 0.5% w/v diethyldithiocarbonate/DMF, DMF 
and DCM. 
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Cyclization: p-nitrophenylchloroformate (0.25 mmol, 5 eq) in dry DCM was added to resin and 
the resin was shaken for 1 hr at rt. Resin was washed with DCM and swelled in 
DMF and treated with 0.5 M DIEA in DMF  for 2 x 15 min. 
Reductive Amination on Solid Support 
Method A: The auxiliary (20 eq.) is dissolved in a mixture of 1:1:1 NMP:MeOH:TMOF +5% 
AcOH  
    (final concentration 0.5 M) and added to resin. After 90 min sodium cyanoborohydride 
(20 
    eq.) in 1:1 NMP:MeOH (final concentration 0.5 M) is added and the reaction is shaken 
at 
    rt for 16 hr. Procedure is repeated if needed. 
Method B: The auxiliary (200 eq.) is dissolved in a mixture of 1:1:1 NMP:MeOH:TMOF +5% 
AcOH  
    (final concentration 0.5 M) and added to resin. After 90 min sodium cyanoborohydride 
    (200 eq.) in 1:1 NMP:MeOH (final concentration 0.5 M) is added and the reaction is 
    shaken at rt for 16 hr. Procedure is repeated if needed. 
Method C: The auxiliary (20 eq.) and sodium cyanoborohydride (20 eq.) are dissolved in a 
mixture of 
     3:1 NMP:iPrOH +5% AcOH (final concentration 0.4 M) and added to resin for 4-16 
hr. 
Cleavage from Support and Protecting Groups Removal 
Fmoc Strategy: The dry peptidyl resins or the dry thiolysis residue (250 mg) were treated with 2 
ml 95:2.5:2.5 v/v TFA:H2O:TIS solution for 2 hr. After 2 hr the mixture was transferred to a tube. 
The resin was washed with the cleavage mixture (0.5 ml X 5) and combined washes were united, 
concentrated under an argon flow to ~2 ml and added dropwise to cold diethylether (20 ml). The 
mixture was centrifuged for 15 min at 0 °C. The ether was decanted and the precipitate was 
dissolved in 25 % CH3CN in H2O + 0.1% TFA and lyophilised to dryness.  
Boc Strategy: The dry peptidyl resin (250 mg) is placed in a RBF with a stirring bar. A solution of 
750 µl 2:1 v/v thioanisole: EDT. RBF is cooled in an ice bath and 5 ml TFA is added for 10 min 
followed by drop-wise addition of 500 µl TFMSA. After 2 hr the mixture was collected and resin 
washed with TFA (5X 0.5 ml). Combined washes were concentrated under an argon flow to ~ 2 
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ml and added drop-wise to cold ether (20 ml) and centrifuged for 15 min at 0 °C. The ether was 
decanted and the precipitate was dissolved in 25 % CH3CN in H2O + 0.1% TFA and lyophilised 
to dryness. 
tert-Butyl Deprotection from Peptides 3.034-3.041 
Method A:   The dry peptidyl resin (250 mg) is placed in a round bottom flask with a stirring bar. 
A solution of 750 µl 2:1 v/v thioanisole: EDT. RBF is cooled in an ice bath and 5 ml 
TFA is added for 10 min followed by drop-wise addition of 500 µl TFMSA. After 2 
hr the mixture was collected and resin washed with TFA (5X 0.5 ml). Combined 
washes were concentrated under an argon flow to ~ 2 ml and added drop-wise to cold 
ether (20 ml) and centrifuged for 15 min at 0 °C. The ether was decanted and the 
precipitate was dissolved in 25 % CH3CN in H2O + 0.1% TFA and lyophilised to 
dryness. 
Method B:   The crude lyophilized peptide is dissolved in cold TFA (concentration of 0.05-0.1 M) 
and placed in an ice-bath. Mercury acetate (2 eq.) is added and mixture is left at 0 °C 
for 30 min. Dithiothreitol (4 eq.) is added and mixture is left at 0 °C for another 10 
min. The mixture is centrifuged and the supernatant is collected. The mercuric 
sulphide salt precipitate is washed with TFA, centrifuged and supernatant is collected 
again. The procedure is repeated 3 times and the united TFA washes are 
concentrated, diluted to 900 µl with water and purified by preparative HPLC. 
Native Chemical Ligation 
Method A: thioester and auxiliary peptide in H2O +0.1% TFA solution are mixed together in a 
ratio 1.2-1.4:1 respectively and lyophilized. The solid mixture is dissolved in a buffer 
containing 0.1 M NaH2PO4, 20 mM TCEP, 3%v/v PhSH, pH 7.5. pH is adjusted to 7.5 
with 0.1 M NaOH (final concentration 5 mM) and reaction is shaken at 25 °C. The 
progress of reaction was monitored using UPLC-MS. Ligation product was isolated by 
semi-preparative HPLC. 
Method B: thioester and auxiliary peptide in H2O +0.1% TFA solution are mixed together in a 
ratio of 1.2:1 respectively and lyophilized. The solid mixture is dissolved in a buffer 
containing 6 M Gn.HCl, 0.1 M NaH2PO4, 20 mM TCEP, 2% v/v PhSH, and BzlSH pH 
7.5. pH is adjusted to 7.5 with 0.1 M NaOH (final concentration 5 mM) and reaction is 
incubated at 25 °C. The progress of reaction was monitored using UPLC-MS. Ligation 
product was isolated using semi-preparative HPLC. 
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Auxiliary Removal 
 
Method A: The pure auxiliary modified ligation product was dissolved in an aqueous buffer of 
140 mM morpholine and 20 mM TCEP pH 8.5 to a concentration of 2 mM and 
incubated at 60 °C for 6 hr. The reaction is quenched by diluting it with H2O + 0.1% 
TFA and directly purified by semi-preparative HPLC. 
Method B: The pure auxiliary modified ligation product was dissolved in 50 µl aqueous buffer 
containing 400 mM morpholine and 100 mM TCEP pH 8.5 to a concentration of 2 
mM and incubated at 50 °C for 6 hr. The reaction is quenched by diluting it with H2O 
+ 0.1% TFA and directly purified by semi-preparative HPLC. 
Method C: To the crude auxiliary modified ligation product in 100 µl aqueous buffer of 250 mM 
imidazole and 10 mM TCEP is added 100 µl aqueous buffer containing 400 mM 
morpholine and 100 mM TCEP pH 8.5 (final concentration 0.05 mM) and incubated at 
25 °C for 24 hr. Reaction is quenched by diluting with H2O + 0.1% TFA and directly 
purified by semi-preparative HPLC. 
 
Auxiliary-Assisted Solid Phase Chemical Ligation 
 
Loading Ni-NTA resin with His-Tag peptides: The Ni-NTA resin (50% suspension in 30% 
EtOH:H2O, 1.2 eq., 70 mg/ml) was swelled in a buffer containing 6M Gn.HCl, 0.1 M 
NaH2PO4 pH 7.2 for 30 min. His-Tag peptide (1 eq.) dissolved in same buffer was 
added to resin for 60 min and resin is washed with the buffer (X5). 
C→N directed SPCL: To the Ni-NTA resin bound auxiliary peptide (1 eq.) was added the 
thioester peptide fragment (1.2 eq.) dissolved in a buffer containing 6 M Gn.HCl, 0.1 
M NaH2PO4, 20 mM TCEP, 10 mM MPAA pH 7.2 to a concentration of 5 mM and 
reaction was shaken at 25 °C for 16 hr. The process was repeated if needed using 0.5 
eq. of thioester peptide. 
N→C directed SPCL: To the Ni-NTA resin bound thioester peptide (1 eq.) was added the 
auxiliary peptide (1.2 eq.) dissolved in a buffer containing 6 M Gn.HCl, 0.1 M 
NaH2PO4, 20 mM TCEP, 10 mM MPAA pH 7.2 to a concentration of 5 mM and 
reaction was shaken at 25 °C for 16 hr. The process is repeated if needed using 0.5 eq. 
of auxiliary peptide. 
Elution of His-Tag peptides from Ni-NTA resin: The resin was thoroughly washed with buffer 
containing 6 M Gn.HCl, 0.1 M NaH2PO4, 20 mM TCEP pH 7.2, water, 0.1% TFA in 
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water, and water. Elution buffer containing 250 mM imidazole and 10 mM TCEP pH 
8.0 (40 µl) was added for 30 min. The elution buffer was collected and process is 
repeated again. The resin was then washed with the elution buffer (2 X 10 µl) and all 
washes are combined. 
Transthioesterification on Ni-NTA Resin: the resin bound peptide benzyl thioester was treated 
with a buffer containing 6M Gn.HCl, 0.1 M NaH2PO4, 40 mM thiol, pH 7.0 and incubated at 25 
°C for 16 hr. 
Converting Peptide Hydrazides to Peptide Thioesters:  
Method A: The resin bound peptide hydrazide was treated with a buffer containing 6M Gn.HCl, 
0.1 M   
                  NaH2PO4, 30 mM NaNO2 pH 3.0 at -10 °C for 20 min, washed and treated with buffer    
                  containing 6M Gn.HCl, 0.1 M NaH2PO4, 20 mM thiol pH 7.2 at 25 °C for 30 min. 
Method B: Peptide hydrazide was dissolved in buffer containing 6M Gn.HCl, 0.1 M NaH2PO4, 30  
                   mM NaNO2 pH 3.0 at -10 °C for 20 min. To the mixture a buffer containing 6M 
Gn.HCl,  
                   0.1 M NaH2PO4, 20 mM thiol pH 7.2 is added at 25 °C for 30 min.  
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5.3 Experimental Data for NCL Assisted by Base-Labile 
Auxiliary 
5.3.1 Synthesis of Auxiliary Precursors 
 
 
Ethyl 4-tertbutylsulfonyl-3-oxobutanoate (3.021):  K2CO3 (1 gr, 7.3 mmol, 1.2 eq) was 
suspended in 12 ml DMF. Tert-butylthiol (820 µl, 7.3 mmol,, 1.2 eq) is added and the mixture is 
stirred at rt for 30 min. Ethyl 4-chloro-3-oxobutanoate 3.020 (1 gr, 900 µl, 6.1 mmol, 1.21 gr/ml, 
1 eq), is added and mixture is further stirred at rt for 3 hr. Ethyl acetate (15 ml) and water (15 ml) 
are added to the reaction. Phases are separated and organic phase is washed with water (3 X 10 
ml) and brine (5 ml), dried over Na2SO4, filtered and concentrated under reduced pressure to yield 
pure ethyl 4-tertbutylsulfonyl-3-oxobutanoate 3.021 with quantitative yield (1.3 gr, 6 mmol). 1H 
NMR (CDCl3, 300 MHz): δ= 4.18 (q, 2H, J= 7.2 Hz , OCH2CH3), 3.68 (s, 2H, 
tBuSCH2C(O)), 
3.43 (s, 2H, C(O)CH2C(O)), 1.30 (s, 9H, C(CH3)3), 1.26 (t, 3H, J= 7.1 Hz , OCH2CH3) 
13C NMR 
(CDCl3, 75 MHz): δ= 200.5, 167.3, 62.0, 46.5, 43.6, 39.7, 30.7, 14.0 0. ESI-MS (CHCl3: MeOH) 
m/z: Calculated for [C10H19O3S]
+:  219.1049 Da [C10H18O3SNa]
+: 241.0869 Da. Observed: 
219.1051 [M+H+], 241.0871 [M+Na+]. 
 
 
4-bromoacetoacetamide (3.023): Acetoacetamide 3.022 (500 mg, 4.95 mmol, 1 eq) is suspended 
in 1.5 ml CHCl3 (C=3.3 M) and cooled in an ice bath to 0 °C. Bromine (280 µl, 5.45 mmol, 1.1 
eq) in 1 ml CHCl3 is added drop-wise and mixture is further stirred at 0 °C for 2 hr. Ice is added 
to the reaction and product is extracted with chloroform (5 X 3 ml). Combined organic phases are 
dried over Na2SO4, filtered and concentrated under reduced pressure to yield 4-
bromoacetoacetamide 3.023 as dark brown oil that was uses without further purification. 
4-tertbutylsulfonylacetoacetamide (3.024): K2CO3 (825 mg, 5.95 mmol, 1.2 eq) was suspended 
in 5 ml DMF. Tert-butylthiol (670 µl, 5.95 mmol, 1.2 eq) is added and the mixture is stirred at rt 
for 10 min. 3.023 (4.95 mmol, 1 eq) is dissolved in 5 ml DMF and added to the reaction mixture. 
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Reaction is allowed to stir at rt for 2 hr. Ethyl acetate (15 ml) and water (15 ml) are added to the 
reaction. Phases are separated and organic phase is washed with water (3 X 10 ml) and brine (5 
ml), dried over Na2SO4, filtered and concentrated under reduced pressure. Column purification 
yielded pure 4-tertbutylsulfonylacetoacetamide 3.024 as a red oil (234 mg, 1.24 mmol, 25%). 1H 
NMR (MeOD-D4, 300 MHz): δ= 3.01 (s, 2H, C(O)CH2C(O)), 2.88 (2, 2H, -SCH2C(O)), 1.35 (s, 
4.5H, C(CH3)3) 
13C NMR (MeOD-D4, 75 MHz): δ= 163.5, 35.6, 30.2, 29.7 ESI-MS (MeOH) m/z: 
Calculated for [C8H16NO2S]
+:  190.0896 Da [C8H15NO2SNa]
+: 212.0716 Da [C8H15NO2SK]
+: 
228.0455 Da Observed: 190.0898 [M+H+], 212.0718 [M+Na+], 228.0458 [M+K+]. 
 
 
(S)-Ethyl 4-tertbutylsulfonyl-3-hydroxybutanoate (3.026):  Cs2CO3 (2.4 gr, 7.5 mmol, 2.5 eq.) 
was suspended in 6 ml DMF. Tert-butylthiol (760 µl, 7.5 mmol, 2.5 eq.) is added and the mixture 
is stirred at rt for 30 min. Ethyl 4-chloro-3-hydroxybutanoate 3.025 (420 µl, 3 mmol, 1 eq.) is 
added and mixture is further stirred at rt for 3 hr Ethyl acetate (10 ml) and water (10 ml) are added 
to the reaction. Phases are separated and organic phase is washed with water (3 X 10 ml) and 
brine (5 ml), dried over Na2SO4, filtered and concentrated under reduced pressure to yield pure 
ethyl 4-tertbutylsulfonyl-3-hydroxybutanoate 3.026 as colorless oil with quantitative yield (635 
mg, 2.9 mmol). 1H NMR (CDCl3, 500 MHz): δ= 4.19 (q, 2H, J= 7.2 Hz , OCH2CH3), 3.17 (d, 1H, 
J= 3.8 Hz, CH2CHOH), 2.63 (m, 4H, CH2CHOHCH2)), 1.35 (s, 9H, C(CH3)3), 1.29 (t, 3H, J= 7.1 
Hz , OCH2CH3) 
13C NMR (CDCl3, 125 MHz): δ= 172.2, 67.5, 60.8, 42.6, 40.4, 35.0, 31.0, 14.2 
ESI-MS (MeOH) m/z: Calculated for [C10H21O3S]
+:  221.1206 Da [C10H21O3S Na]
+: 243.1025 Da 
[C14H21NO2S K]
+: 259.0975 Da Observed: 221.1209 [M+H+], 243.1029 [M+Na+], 259.0979 
[M+K+]. 
(S)-4-tertbutylsulfonyl-3-hydroxy-N-phenylbutanamide (3.027): Aniline (228 µl, 2.5 mmol, 
2.5 eq.) is dissolved in 7 ml CH2Cl2 and cooled to 0 °C. 2 M Trimethylaluminum in heptane (1.25 
ml, 2.5 mmol, 2.5 eq.) is added and mixture is stirred at 0 °C for 1 hr. 3.026 (220 mg, 1 mmol, 1 
eq.) is dissolved in 3 ml CH2Cl2 and added drop-wise to the mixture and the reaction is refluxed 
for 2 hr. Reaction is cooled to 0 °C, diluted with 10 ml CH2Cl2, cold 3 M aqueous HCl (20 ml) is 
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added drop-wise and stirred for 1 hr. Layers are separated and aqueous layer is washed with 
CH2Cl2 (3 X 10 ml). Combined organic layers are dried over Na2SO4, filtered and concentrated 
under reduced pressure. The crude is then purified using column chromatography (3:7 EtOAc: 
cHex) to yield 3.027 as a white solid. (250 mg, 0.95 mmol, 95% yield) 1H NMR (CDCl3, 500 
MHz): δ= 8.10 (s(br), 1H, NHPh) 7.53 (d, 2H, J= 7.5 Hz , 2XArH), 7.33 (t, 2H, J= 7.5 Hz , 
2XArH), 7.14 (t, 1H, J= 7.5 Hz , ArH), 4.15 (m, 1H, CHOH), 3.70 (s(br), 1H, OH), 2.70 (m, 4H, 
CH2CHOHCH2), 1.36 (s, 9H, C(CH3)3) 
13C NMR (CDCl3, 125 MHz): δ= 169.5, 137.7, 129.0, 
124.4, 120.0, 67.6, 43.1, 43.0, 35.6, 31.1 ESI-MS (CHCl3: MeOH) m/z: Calculated for 
[C14H22NO2S]
+:  268.1366 Da [C14H21NO2S Na]
+: 290.1185 Da [C14H21NO2S K]
+: 306.0925 Da 
Observed: 268.1368 [M+H+], 290.1187 [M+Na+], 306.0928 [M+K+]. 
(S)-4-tertbutylsulfonyl-3-oxo-N-phenylbutanamide (3.028): Dess-Martin periodinane 15% 
weight solution in CH2Cl2 (3.2 ml, 1.7 mmol, 1.05 eq) is dissolved in 12 ml CH2Cl2. Tert-butanol 
(164 µl, 1.72 mmol, 1.06 eq) is added and mixture is stirred at rt for 20 min. 3.027 (430 mg, 1.62 
mmol, 1 eq.) is dissolved in 3 ml CH2Cl2 and added to the mixture and reaction is allowed to stir 
at rt for 20 min. Reaction is diluted with ether (15 ml) and poured into a solution of 0.3 N sodium 
thiosulfate pentahydrate in 1 N sodium bicarbonate (60 ml) and stirred for 20 min. Layers are 
separated and organic phase is washed with 1N NaHCO3 (15 ml), water (15 ml) and brine (10 ml), 
dried over Na2SO4, filtered and concentrated under reduced pressure. The crude is purified using 
column chromatography (1:1 EtOAc: cHex) to yield the desired product 3.028 as brown oil (345 
mg, 1.30 mmol, 80% yield). 1H NMR (CDCl3, 500 MHz): δ= 8.93 (s(br), 1H, NHPh) 7.55 (d, 2H, 
J= 7.5 Hz , 2XArH), 7.33 (t, 2H, J1,2= 7.5 Hz, J2,3= 8.3 Hz, 2XArH), 7.14 (t, 1H, J= 7.4 Hz, ArH), 
3.81 (s, 2H, C(O)CH2C(O)), 3.48 (s, 2H, -SCH2C(O)), 1.35 (s, 9H, C(CH3)3) 
13C NMR (CDCl3, 
125 MHz): δ= 204.2, 163.4, 137.5, 129.0, 124.6, 120.1, 47.3, 43.9, 40.5, 30.7 ESI-MS (CHCl3: 
MeOH) m/z: Calculated for [C14H20NO2S]
+:  266.1209 Da [C14H21NO2S Na]
+: 288.1029 Da 
[C14H21NO2S K]
+: 304.0768 Da Observed: 266.1212 [M+H+], 288.1032 [M+Na+], 304.0071 
[M+K+]. 
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(S) - 4-tertbutylsulfonyl-3-hydroxybutanoic acid (3.030): 3.026 (700 mg, 3.20 mmol) is 
dissolved in 9 ml THF and 5 ml aqueous solution of 2 N NaOH is added. Reaction is allowed to 
stir at rt for 3 hr then quenched with cold 2 N aqueous HCl solution to pH 2. Product is extracted 
with EtOAc (3 X 10 ml) and combined organic phases are washed with brine (5 ml), dried over 
Na2SO4 and concentrated to yield desired product 3.030 that was used without further purification. 
 
(S) - 4-tertbutylsulfonyl-3-hydroxy-N-methyl-N-phenylbutamide (3.029): 3.030 (340 mg, 1.5 
mmol, 1 eq.) and N-methylaniline (196 µl, 1.8 mmol, 1.2 eq) are dissolved in 3 ml DMF and 
EDC.HCl (345 mg, 1.8 mmol, 1.2 eq) is added. Reaction is stirred at rt O.N. Ethyl acetate (5 ml) 
is added and washed with water (3 X 5 ml). Organic phase is dried over Na2SO4, filtered and 
concentrated under reduced pressure. Purification with column chromatography (1:1 EtOAc: 
cHex) gave 3.029 (168 mg, 0.60 mmol, 40% yield over 3 steps). 1H NMR (CDCl3, 500 MHz): δ= 
7.42 (m, 3H, 3XArH) 7.22 (d, 2H, J= , 2XArH), 4.07 (m, 1H,  CHOH), 3.30 (s, 3H, NCH3Ph), 
2.40 (m, 4H, CH2COHCH2), 1.28 (s, 9H, C(CH3)3) 
13C NMR (CDCl3, 125 MHz): δ= 171.7, 142.8, 
129.5, 127.7, 126.8, 68.0, 41.9, 38.9, 36.7, 34.1, 30.5 ESI-MS (CHCl3: MeOH) m/z: Calculated 
for [C15H24NO2S]
+: 282.1522 Da [C15H23NO2SNa]
+: 304.1342 Da [C14H21NO2SK]
+: 320.1081 Da 
Observed: 282.1526 [M+H+], 304.1345 [M+Na+], 320.1086 [M+K+]. 
4-tertbutylsulfonyl-3-oxo-N-methyl-N-phenylbutamide (3.031): Dess-Martin periodinane 
15%weight solution in CH2Cl2 (3.1 ml, 1.60 mmol, 1.05 eq) is dissolved in 10 ml CH2Cl2. Tert-
butanol (157 µl, 1.62 mmol, 1.06 eq) is added and mixture is stirred at rt for 20 min. 3.029 (430 
mg, 1.53 mmol, 1 eq.) is dissolved in 4 ml CH2Cl2 and added to the mixture. Reaction is allowed 
to stir at rt for 20 min. Reaction is diluted with ether (15 ml) and poured into a solution of 0.3 N 
sodium thiosulfate pentahydrate in 1 N sodium bicarbonate (60 ml) and stirred for 20 min. Layers 
are separated and organic phase is washed with 1N NaHCO3 (10 ml), water (10 ml) and brine (5 
ml), dried over Na2SO4, filtered and concentrated under reduced pressure. The crude is purified 
using column chromatography (1:1 EtOAc: cHex) to yield 3.031 as brown oil. (300 mg, 1.1 
mmol, 70% yield). 
1
H NMR (CDCl3, 500 MHz): δ= 7.42 (m, 3H, 3XArH), 7.25 (m, 2H, 2XArH), 
3.52 (s, 2H, C(O)CH2C(O)), 3.35 (s, 2H, -SCH2C(O)), 3.51 (s, 3H, NCH3Ph), 1.24 (s, 9H, 
C(CH3)3) 
13C NMR (CDCl3, 125 MHz): δ= 202.0, 166.9, 143.5, 130.0, 128.3, 127.3, 46.5, 43.4, 
39.8, 37.3, 30.7. ESI-MS ( CHCl3: MeOH) m/z: Calculated for [C15H22NO2S]
+:  280.1366 Da 
[C14H21NO2SNa]
+: 302.1185 Da [C14H21NO2S K]
+: 318.0925 Da Observed: 268.1369 [M+H+], 
302.1189 [M+Na+], 318.0929 [M+K+]. 
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Ethyl 3-oxo-4-(tritylthio)butanoate (3.070): K2CO3 (423 mg, 3.04 mmol, 1 eq) was suspended 
in 6ml DMF. Triphenylmethylthiol (756 mg, 2.74, 0.9 eq) is added and the mixture is stirred at rt 
for 10 min. Ethyl -chloro-3-oxobutanoate 3.20 (410 µl, 3.04 mmol, 1 eq) is added and mixture is 
further stirred at rt for 3 hr. Ethyl acetate (15 ml) and water (15 ml) are added to the reaction. 
Phases are separated and organic phase is washed with water (3 X 10 ml) and brine (5 ml), dried 
over Na2SO4, filtered and concentrated under reduced pressure. Crude is purified by column (3:17 
EtOAc/cHex) to yield pure ethyl 4-tertbutylsulfonyl-3-oxobutanoate 3.070 (984 mg ,2.43 mmol, 
80%). 1H NMR (CDCl3, 400 MHz): δ= 7.45-7.23 (m, 15H, 15X ArH) 4.13 (q, 2H, J= 7.2 Hz , 
OCH2CH3), 3.26 (s, 2H, 
tBuSCH2C(O)), 3.21 (s, 2H, C(O)CH2C(O)), 1.24 (t, 3H, J= 7.1 Hz , 
OCH2CH3) 
13C NMR (CDCl3, 125 MHz): δ= 198.5, 144.0, 129.5, 128.2, 127.0, 61.4, 47.3, 42.7, 
14.0 ESI-MS (CHCl3: MeOH) m/z: Calculated for [C25H24NO3S Na]
+: 427.1338 Da [C14H21NO2S 
K]+: 443.1078 Da Observed: 427.1349 [M+Na+], 443.1088 [M+K+]. 
5.3.2 Synthesis of Model Peptides 
 
Synthesis of peptides GRAEYSGLG (3.32) and ARAEYSGLG (3.33): The peptides were 
manually synthesized as described in the general protocol on a Rink Amide resin (0.19 mmol/g) 
in a 100 µmol scale.  
 
3.32 H-GRAEYSGLG-NH2: ESI-MS (positive mode): m/z = 909.0 [M+H]
+1, 455.0 [M+2H]+2, 
Calculated Mass: 909.0 Da [M+H]+1, 455.0 [M+2H]+2. 
ESI-MS (positive mode): m/z = 909.0 (C38H62N13O13 [M+H]
+1, calcd.: 737.9 ), 455.0 
(C38H63N13O13 [M+2H]
+2, calcd.: 455.0).  
 
3.33 H-ARAEYSGLG- NH2: Observed Mass: 923.0 g/mol [M+H]
+1, 462.0 [M+2H]+2, Calculated 
Mass: 923.0 Da [M+H]+1, 462.0 [M+2H]+2. 
ESI-MS (positive mode): m/z = 923.0 (C39H64N13O13 [M+H]
+1
, calcd.: 923.0 ), 462.0 
(C39H65N13O13 [M+2H]
+2, calcd.: 462.0).  
 
 
Synthesis of thioester peptides LYRAG-MPA-G (3.52) and LYRAA-MPA-G (3.53) using 
Boc SPPS: MBHA resin (149.2 mg, 0.67 mmol/gr, 0.1 mmol) is swelled for 30 min in DMF, 
treated with 10% v/v solution of DIEA in DMF (2 X 5 min, 1 ml) and washed with DMF (X5).  
Fmoc-Gly-OH (70 mg, 0.4 mmol, 4 eq.), HCTU (165 mg, 0.4 mmol, 4 eq), HOBt (54 mg, 0.4 
mmol, 4 eq) and NMM (88 µl, 0.8 mmol, 8 eq.) in 1 ml DMF is added to resin and coupled for 1 
hr. Fmoc deprotection was performed and loading was measured to be quantitative. Resin is 
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washed with DMF (X5) and Trt-MPA-OH (139.4 mg, 0.4 mmol, 4 eq.), HCTU (165 mg, 0.4 
mmol, 4 eq), HOBt (54 mg, 0.4 mmol, 4 eq) and NMM (88 µl, 0.8 mmol, 8 eq.) in 1 ml DMF is 
added to resin and coupled for 2 hr. Resin is washed with DMF (X5), capped, washed with DMF 
(X5) and DCM (X10), dried and weighted. Divided into 2 reaction vessels (98 mg, 50 µmol) and 
swelled in DCM. Trt group is deprotected by treatment with a mixture of 90:5:5v/v 
TFA:TES:H2O (2X5 min, 1 ml). Resin washed with DCM (X10) and DMF (X5). Rest of the 
sequence was synthesized as described in the general protocol. 
 
3.52 H-LYRAG-MPA-G-NH2: 21.7 mg, 722.8 g/mol, 30 µmol, 60%. C31H51N11O7S, 722.88 
g/mol. UPLC: tR = 1.10 min (03% B – 60% B in 2 min, ESI-MS (positive mode): m/z = 723.8 
(C31H52N11O7S [M+H]
+1, calcd.: 723.9 ), 362.4 (C31H53N11O7S [M+2H]
+2, calcd.: 362.4).   
3.53 H-LYRAA-MPA-G-NH2: 22.0 mg, 736.9 g/mol, 30 µmol, 60%.  
ESI-MS (positive mode): m/z = 737.9 (C32H54N11O7S [M+H]
+1, calcd.: 737.9 ), 369.4 
(C32H55N11O7S [M+2H]
+2, calcd.: 369.4).  
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5.3.3 Reductive Amination on Solid Support 
 
Auxiliary precursors 3.021, 3.024, 3.028 and 3.031 were attached to peptides 3.032 and 3.033 
following the general reductive amination protocol method A. 
 
5.3.4 tert-Butyl Protecting Group Removal 
Removal of tert-Butyl using method A: TFMSA:TFA:anisole 
 
 
 
Figure 5.1: HPLC analysis of tert-butyl deprotection using method A to give unprotected 
auxiliary peptides 3.042-3.049; peaks 3.032 and 3.033 correspond to peptides GRAYESGLG and 
ARAEYSGLG respectively; peak 3.032* and 3.033* correspond to N-acetylation of peptide 
3.032 and 3.033 respectively; Gradient: 03-60% B in 20min, 210 nm. 
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Removal of tert-Butyl using method B: Mercury Acetate 
 
 
 
Figure 5.2: HPLC analysis of tert-butyl deprotection using method B to give unprotected 
auxiliary peptides 3.042-3.045; peaks 3.032 and 3.033 correspond to peptides GRAYESGLG and 
ARAEYSGLG respectively; peak 3.32* and 3.33* correspond to N-acetylation of peptide 3.032 
and 3.033 respectively; Gradient: 03-60% B in 20min, 210 nm. 
 
Removal of tert-butyl group from peptide 3.034 to yield peptide 3.042 was carried out according 
to method B in the general protocol. Purified using preparative HPLC. Gradient 03-60% B in 30 
min. Isolated yield: 3.2 mg, 30%. 
ESI-MS (positive mode): m/z = 1055.2 (C46H72N13O15S [M+H]
+1, calcd.: 1055.2), 528.1 
(C46H73N13O15S [M+2H]
+2, calcd.: 528.1).  
 
Removal of tert-butyl group from peptide 3.035 to yield peptide 3.043 was carried out according 
to method B in the general protocol. Purified using preparative HPLC. Gradient 03-60% B in 30 
min. Isolated yield: 1.5 mg, 14%. 
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ESI-MS (positive mode): m/z = 1069.2 (C47H74N13O15S [M+H]
+1, calcd.: 1069.2), 535.1 
(C47H75N13O15S [M+2H]
+2, calcd.: 535.1).  
 
Removal of tert-butyl group from peptide 3.036 to yield peptide 3.044 was carried out according 
to method B in the general protocol. Purified using preparative HPLC. Gradient 03-60% B in 30 
min. Isolated yield: 2.4 mg, 24%. 
ESI-MS (positive mode): m/z = 1026.3 (C42H69N14O14S [M+H]
+1, calcd.: 1026.2), 513.6 
(C42H70N14O14S [M+2H]
+2, calcd.: 513.6). 
 
Removal of tert-butyl group from peptide 3.037 to yield peptide 3.045 was carried out according 
to method B in the general protocol. Purified using preparative HPLC. Gradient 03-60% B in 30 
min. Isolated yield: 1.9 mg, 18%. 
ESI-MS (positive mode): m/z = 1040.2 (C43H71N14O14S [M+H]
+1, calcd.: 1040.2), 520.5 
(C43H72N14O14S [M+2H]
+2, calcd.: 513.6). 
 
Removal of tert-butyl group from peptide 3.038 to yield peptide 3.046 was carried out according 
to method A in the general protocol. Purified using preparative HPLC. Gradient 03-60% B in 30 
min. Isolated yield: 4 mg, 36%. 
ESI-MS (positive mode): m/z = 1102.4 (C48H73N14O14S [M+H]
+1, calcd.: 1102.3), 551.6 
(C48H74N14O14S [M+2H]
+2, calcd.: 551.6). 
 
Removal of tert-butyl group from peptide 3.039 to yield peptide 3.047 was carried out according 
to method B in the general protocol. Purified using preparative HPLC. Gradient 03-60% B in 30 
min. Isolated yield: 1.7 mg, 15%. 
ESI-MS (positive mode): m/z = 1116.4 (C49H75N14O14S [M+H]
+1, calcd.: 1116.3), 558.7 
(C49H76N14O14S [M+2H]
+2, calcd.: 558.7). 
 
Removal of tert-butyl group from peptide 3.040 to yield peptide 3.048 was carried out according 
to method B in the general protocol. Purified using preparative HPLC. Gradient 03-60% B in 30 
min. Isolated yield: 1.8 mg, 16%. 
ESI-MS (positive mode): m/z = 1116.2 (C49H75N14O14S [M+H]
+1, calcd.: 1116.3), 558.7 
(C49H76N14O14S [M+2H]
+2, calcd.: 558.7). 
 
Removal of tert-butyl group from peptide 3.041 to yield peptide 3.049 was carried out according 
to method B in the general protocol. Purified using preparative HPLC. Gradient 03-60% B in 30 
min. Isolated yield: 1.7 mg, 15%. 
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ESI-MS (positive mode): m/z = 1130.4 (C50H77N14O14S [M+H]
+1, calcd.: 1130.3), 565.7 
(C50H78N14O14S [M+2H]
+2, calcd.: 565.7). 
5.3.5 Auxiliary-Assisted Native Chemical Ligations: 
Ligations were performed according to NCL method A as described in the general procedure.  
Table 5.1: Ligation yields 
 
TE (Z) AP-(X-R) LP Yield
a
 (t) Isolated yield 
3.052 (G) 3.034 (G-OEt) 3.054 99%(4 hr) 56% 
3.052 (G) 3.035 (A-OEt) 3.056 65% (8 hr) 41% 
3.052 (G) 3.036 (G-NH2) 3.058 50% (2 hr) ND 
3.052 (G) 3.038 (G-NHPh) 3.060 905 (4 hr) 57% 
3.052 (G) 3.039 (A-NHPh) 3.062 80% (4 hr) 37% 
3.052 (G) 3.040 (G-NMePh) 3.064 37% (24 hr) ND 
3.052 (G) 3.041 (A-NMePh) 3.065 27% (24 hr) ND 
3.053 (A) 3.034 (G-OEt) 3.055 50% (8 hr) 10 % 
3.053 (A) 3.035 (A-OEt) 3.057 ND ND 
3.053 (A) 3.036 (G-NH2) 3.059 28% (4 hr) ND 
3.053 (A) 3.038 (G-NHPh) 3.061 80% (8 hr) 17% 
3.053 (A) 3.039 (A-NHPh) 3.063 ND ND 
3.053 (A) 3.040 (G-NMePh) 3.065 14% (24 hr) ND 
3.053 (A) 3.041 (A-NMePh) 3.067 ND ND 
ayields were calculated by means of HPLC based on ratios of peak areas.  
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Figure 5.3: A) UPLC chromatogram of pure ligation product 3.054; B) ESI-MS of ligation 
product 3.054; 03-60% B in 6 min, 210 nm. 
 
ESI-MS (positive mode): m/z = 808.4 (C70H112N21O21S [M+2H]
+2, calcd.: 808.4), 539.3 
(C70H113N21O21S [M+3H]
+3, calcd.: 539.3). 
 
 
 
Figure 5.4: A) UPLC chromatogram of purified ligation product 3.055 showing spontaneous 
formation of thiolactone 3.050 from ligation product 3.055;B) ESI-MS of ligation product 3.055; 
03-60% B in 6 min, 210 nm. 
 
ESI-MS (positive mode): m/z = 815.4 (C71H114N21O21S [M+2H]
+2, calcd.: 815.4), 543.9 
(C70H115N21O21S [M+3H]
+3, calcd.: 543.9). 
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Figure 5.5: A) UPLC chromatogram of pure ligation product 3.056;B) ESI-MS of ligation 
product 3.056; 03-60% B in 6 min, 210 nm. 
 
ESI-MS (positive mode): m/z = 837.4 (C71H113N21O21SNa2 [M+2Na]
+2, calcd.: 837.4),815.4 
(C71H114N21O21S [M+2H]
+2, calcd.: 815.4), 543.9 (C70H115N21O21S [M+3H]
+3, calcd.: 543.9). 
 
 
Figure 5.6: Ligation between thioester 3.053 and peptide auxiliary 3.043 at 0 hr and 24 hr; 03-
60% B in 6 min, 210 nm. 
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Figure 5.7: Time vs. yield for products 3.054-3.057. 
 
 
 
Figure 5.8: ESI-MS of ligation product 3.058. 
 
ESI-MS (positive mode): m/z = 793.7 (C68H109N22O20S [M+2H]
+2, calcd.: 793.9), 529.5 
(C68H110N22O20S [M+3H]
+3, calcd.: 529.6). 
 
Figure 5.9: ESI-MS of ligation product 3.059. 
 
ESI-MS (positive mode): m/z = 800.7 (C69H111N22O20S [M+2H]
+2, calcd.: 800.9), 534.1 
(C69H113N22O20S [M+3H]
+3, calcd.: 534.3). 
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Figure 5.10: Time vs. yield for products 3.058, 3.059. 
 
 
 
Figure 5.11: A) UPLC chromatogram of purified ligation product 3.060;B) ESI-MS of ligation 
product 3.060; Peak * corresponds to unidentified masses; 03-60% B in 6 min, 210 nm. 
 
ESI-MS (positive mode): m/z = 1662.2 (C74H113N22O20S [M+H]
+1
, calcd.: 1662.9), 831.6 
(C74H114N22O20S [M+2H]
+2, calcd.: 832.0) , 554.7 (C74H115N22O20S [M+3H]
+3, calcd.: 555.0). 
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Figure 5.12: A) UPLC chromatogram of purified ligation product 3.061;B) ESI-MS of ligation 
product 3.061; 03-60% B in 6 min, 210 nm. 
ESI-MS (positive mode): m/z = 838.9 (C75H115N22O20S [M+2H]
+2, calcd.: 839.0), 559.6 
(C75H116N22O20S [M+3H]
+3, calcd.: 559.7). 
 
Figure 5.13: A) UPLC chromatogram of purified ligation product 3.062;B) ESI-MS of ligation 
product 3.062; 03-60% B in 6 min, 210 nm. 
 
ESI-MS (positive mode): m/z = 838.8 (C75H115N22O20S [M+2H]
+2, calcd.: 839.0), 559.6 
(C75H116N22O20S [M+3H]
+3, calcd.: 559.7). 
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Figure 5.14: Ligation between thioester 3.053 and peptide auxiliary 3.047 at 0 hr and 24 hr; 03-
60% B in 6 min, 210 nm. 
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Figure 5.15: Time vs. yield for products 3.060- 3.063. 
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Figure 5.16: ESI-MS of ligation product 3.064. 
 
ESI-MS (positive mode): m/z = 838.9 (C75H115N22O20S [M+2H]
+2, calcd.: 839.0), 559.6 
(C75H116N22O20S [M+3H]
+3, calcd.: 559.7). 
 
Figure 5.17: Ligation between thioester 3.053 and peptide auxiliary 3.048 to give ligation product 
3.065 at 0 hr and 24 hr. Peak * correspond to unidentified masses; 03-60% B in 6 min, 210 nm. 
 
ESI-MS (positive mode): m/z = 846.0 (C76H117N22O20S [M+2H]
+2, calcd.: 847.0), 564.3 
(C76H118N22O20S [M+3H]
+3, calcd.: 565.0). 
 
Figure 5.18: ESI-MS of ligation product 3.066. 
 
ESI-MS (positive mode): m/z = 846.9 (C76H117N22O20S [M+2H]
+2, calcd.: 846.0), 564.3 
(C76H118N22O20S [M+3H]
+3, calcd.: 564.3). 
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Figure 5.19: ESI-MS of ligation intermediate 3.067* 
 
ESI-MS (positive mode): m/z = 852.9 (C76H117N22O20S [M+2H]
+2, calcd.: 853.0), 568.9 
(C76H118N22O20S [M+3H]
+3, calcd.: 569.0) , 427.0 (C76H119N22O20S [M+4H]
+4, calcd.: 427.0). 
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Figure 5.20: Time vs. yield for products 3.064- 3.067. 
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5.3.6 Removal of Auxiliary 
Auxiliary removal was performed as described in method A in the general protocol. 
 
Figure 5.21: UPLC analysis showing the removal of auxiliary from ligation product 3.054 to give 
native peptide 3.068 (A) and from ligation product 3.055 to give native peptide 3.069 (B) at 0 and 
6 hr; Gradient: 03-60% B in 4 min, 210 nm. 
 
 
Figure 5.22: UPLC analysis showing the removal of auxiliary from ligation product 3.060 to give 
native peptide 3.068 (A) and from ligation product 3.061 to give native peptide 3.069 (B) at 0 and 
7 hr; Gradient: 03-60% B in 4 min, 210 nm. 
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5.3.7 Total synthesis of DCD-1L 
Ligation and Auxiliary Removal: Ligation was performed using method A as described in the 
general protocol in 1.2 µmol scale. 
 
Figure 5.23: Synthesis of DCD-1L. A) Scheme depicting synthetic route; B) UPLC analysis of 
ligation between Der1 and Der2 and auxiliary removal to yield native DCD-1L; C) MS analysis 
Der12 with observed mass 4963.6 Da (calc. 4963.7 Da); D) MS analysis of DCD-1L with 
observed mass 4817.4 Da (calc. 4817.5 Da); 03-70% B in 6 min, 210 nm. 
Der12 H-Der(63-78)-Aux-Der(69-110)-NH2 3.0 mg, 4963.7 gr/mol, 0.60 µmol, 50% 
ESI-MS (positive mode): m/z = 993.7 (C216H379N58O72S [M+5H]
+5, calcd.: 993.8) , 828.3 
(C216H380N58O72S [M+6H]
+6, calcd.: 828.3), 710.1 (C216H381N58O72S [M+7H]
+7, calcd.: 710.1), 
621.5 (C216H382N58O72S [M+8H]
+8, calcd.: 621.5), 552.5 (C216H382N58O72S [M+9H]
+9, calcd.: 
552.5). 
DCD-1L H-Der(63-110)-NH2, 1.2 mg, 4817.5 gr/mol, 0.24 µmol, 40% 
ESI-MS (positive mode): m/z = 1205.4 (C210H364N58O70 [M+4H]
+4, calcd.: 1205.4), 964.5 
(C210H365N58O70 [M+5H]
+5, calcd.: 964.5) , 803.9 (C210H366N58O70 [M+6H]
+6, calcd.: 803.9), 689.2 
(C210H367N58O70 [M+7H]
+7, calcd.: 689.2), 603.2 (C210H368N58O70 [M+8H]
+8, calcd.: 603.2). 
 
Stability of peptides to long exposure of auxiliary removal buffer 
To test the protein stability under the removal conditions pure Dermicidin-1L DCD-1L was 
redissolved in the removal buffer and shaken for 24 hr with aliquots taken at 3, 6 and 24 hr. 
results indicated that the peptide is stable for prolonged treatment with small side-products 
appearing after 24 hr. The side-products showed same mass as the original protein probably 
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hinting towards racemization of different residues after the long treatment at an elevated 
temperature and pH (figure 5.24). 
 
Figure 5.24: UPLC analysis of pure Der-1L in auxiliary removal buffer over time. A) 0 hr, B) 3 
hr, C) 6hr, D) 24 hr, 03-70%B in 6 min, 210 nm. 
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5.4 Experimental Data for Auxiliary-Assisted SPCL 
5.4.1 Synthesis of Auxiliary Precursor 2-((bis(4-methoxyphenyl) 
(phenyl) methyl)thio)-2-phenylacetaldehyde (3.072) 
The auxiliary 3.072 was synthesized as described in reference [95].  
 
5.4.2 SPPS, Preparation of peptide building blocks and 
Chromatographic Purification of Proteins and Peptides 
Synthesis of Peptides Aux-MUC1(1-20)-His6 (3.079), Aux-MUC1(1-20)-Dbz-Gly (3.086) and 
Aux-MUC1(41-80)-His6 (3.114) 
Sequence of MUC1(1-20): GVTSAPDTRPAPGSTAPPAH  
SPPS: The peptides were synthesized as described in the general protocol on a Rink Amide resin 
(0.19 mmol/g) in a 10 µmol scale.  
Aux-MUC1(1-20)-Dbz-Gly 3.086 was synthesized in a 10 µmol scale as described in the 
general procedure for synthesis of Dbz peptides. 
 
Reductive amination: was performed as described in method C in the general protocol. 
 
Cleavage of protecting groups and isolation of peptide: Performed as described previously under 
the general procedure for cleavage and purification of peptides.  
 
3.079 Aux-MUC1(1-20)-His6 12.4 mg, 3101.0 gr/mol, 4 µmol, 40%, %,  
ESI-MS (positive mode): m/z = 1034.3 (C124H179N44O33S [M+3H]
+3, calcd.: 1034.3), 776.2 
(C124H180N44O33S [M+4H]
+4, calcd.: 776.0) , 621.4 (C124H181N44O33S [M+5H]
+5, calcd.: 621.0), 
517.9 (C124H182N44O33S [M+6H]
+6, calcd.: 517.7), 444.0 (C124H182N44O33S [M+7H]
+7, calcd.: 
443.9). 
 
3.086 Aux-MUC1(1-20)-Dbz-Gly, 7.4 mg, 2468.7 gr/mol ,3 µmol, 30%,  
ESI-MS (positive mode) m/z = 823.9 (C88H139N29O29 [M+3H]3+, calcd: 823.8), 618.4 
(C88H140N29O29 [M+4H]4+, calcd: 618.1), 494.0 (C88H141N29O29 [M+5H]5+, calcd. 494.7). 
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3.114 Aux-MUC1(41-80)-His6 7.0 mg, 4715 gr/mol, 1.5 µmol, 15%.   
ESI-MS (positive mode) m/z =  1179.5 (C204H307N69O60S [M+4H]
4+, calcd. 1179.5), 943.8 
(C204H308N69O60S [M+5H]
5+
, calcd. 943.8) 786.7 (C204H309N69O60S [M+6H]
6+
, calcd. 786.7), 674.5 
(C204H310N69O60S [M+7H]
7+, calcd. 674.4), 590.3 (C204H311N69O60S [M+8H]
8+, calcd. 590.3).  
 
Synthesis of thioester peptide His6-MUC1(1-20)-SBzl (3.093) and H-MUC1(1-40)-SBzl 
(3.094) and His5-MUC1(1-20)-SBzl (3.102) using safety-catch linker approach 
Peptides were synthesized as described in the general protocol in 10 µmol scale. 
 
3.093 His6-MUC1(1-20)-SBzl, 13.8 mg, 3071.6 gr/mol, 4.5 µmol,  45%.
 
ESI-MS (positive mode) m/z =  1024.6 (C123H178N43O34S [M+3H]
3+, calcd. 1024.7), 768.9 
(C123H179N43O34S [M+4H]
4+, calcd. 768.9) 615.4 (C123H180N43O34S [M+5H]
5+, calcd. 615.2), 512.8 
(C123H181N43O34S [M+6H]
6+, calcd. 512.8), 439.7 (C123H182N43O34S [M+7H]
7+, calcd. 439.7).  
 
3.094 H-MUC1(1-40)-SBzl 13.5 mg, 3862 gr/mol, 3.5 µmol, 35%.  
ESI-MS (positive mode) m/z =  966.6 (C167H262N50O55S [M+4H]
4+
, calcd. 966.6), 773.2 
(C167H263N50O55S [M+5H]
5+, calcd. 773.5), 644.5 (C167H264N50O55S [M+6H]
6+, calcd. 644.7), 
552.6 (C167H265N50O55S [M+7H]
7+, calcd. 552.7). 
 
3.102 His5-MUC1(1-20)-SBzl,13.4 mg, 2678.9 gr/mol, 5.0 µmol, 50%.  
ESI-MS (positive mode) m/z =  894.0 (C117H171N40O33S [M+3H]
3+, calcd. 894.0), 670.7 
(C117H172N40O33S [M+4H]
4+, calcd. 670.7), 536.8 (C117H173N40O33S [M+5H]
5+, calcd. 536.8).  
 
Synthesis of Hydrazide Peptide His6-MUC1(1-20)-NHNH2 (3.111) 
Synthesis of hydrazine 2-chlorotrytyl resin: Resin (325 mg, 1.3 mmol/gr, 0.5 mmol) swelled in 
DMF. A mixture of 1:1:1 v/v NEt3: H2O: DMF (1 ml) added for 60 min. and MeOH (1 
ml) is added for 30 min. Resin is washed with MeOH+ 5% v/v DIPEA, MeOH, DMF 
and DCM (X 3 each) and swelled in DMF. 
 
Loading of first amino acid: Fmoc-His(Trt)-OH (31 mg, 0.05 mmol, 5 eq), HCTU (20.7 
mg, 0.05 mmol), HOBt (6.8 mg, 0.05 mmol) and NMM (11 µl, 0.1 mmol, 10 eq) in 125 
µl DMF is added to resin and coupled 2 X 30 min. 
 
SPPS: Rest of peptide was synthesized on an automated peptide synthesizer as described in the 
general protocol. 
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Cleavage of protecting groups and isolation of peptide: Performed as described previously under 
the general procedure for cleavage and purification of peptides.  
 
3.111 His6-MUC1(1-20)-NHNH2 15 mg, 2723.9 gr/mol, 5.5 µmol, 55%.  
ESI-MS (positive mode) m/z =  908.8 (C110H167N42O32 [M+3H]
3+, calcd. 909.0), 682.7 
(C110H168N42O32 [M+4H]
4+, calcd. 682.0), 545.8 (C110H169N42O32 [M+5H]
5+, calcd. 545.8). 
5.4.3 Auxiliary-Assisted SPCL in N→C and C→N direction 
 
Ligation between His6-MUC1(1-20)-SBzl (3.093) and Aux-MUC1(1-20)-Dbz-Gly (3.086): 
done as described in the general protocol. In 0.5 µmol scale to yield product 3.095.  
ESI-MS (positive mode) m/z =  1106.7 (C213H315N73O62SNa5 [M+5H]
5+, calcd. 1107.0), 903.7 
(C213H321N73O62S [M+6H]
6+, calcd. 903.5), 774.7 (C213H322N73O62S [M+7H]
7+, calcd. 774.6), 
667.9 (C213H323N73O62S [M+8H]
8+, calcd. 667.9), 602.9 (C213H343N73O62S [M+9H]
9+, calcd. 
602.7).  
 
Ligation between H-MUC1(1-40)-SBzl (3.094) and Aux-MUC1(1-20)-His6 (3.079): done as 
described in the general protocol. In 0.5 µmol scale to yield product 3.096. ESI-MS (m/z): 
Observed Mass: 1140.7 [M+6H]6+, 977.9 [M+7H]7+, 856.0 [M+8H]8+, 761.0 [M+9H]9+, 685.3 
[M+10H]10+, 622.1 [M+11H]11+  Calculated Mass:. 1140.7 [M+6H]6+, 977.9 [M+7H]7+, 855.8 
[M+8H]8+, 760.8 [M+9H]9+, 684.8 [M+10H]10+622.1 [M+11H]11+. 
ESI-MS (positive mode) m/z =  1140.7 (C284H434N94O87S [M+6H]
6+, calcd. 1140.7), 977.9 
(C284H435N94O87S [M+7H]
7+, calcd. 977.9), 856.0 (C284H436N94O87S [M+8H]
8+, calcd. 856.0), 
761.0 (C284H437N94O87S [M+9H]
9+, calcd. 760.8), 685.3 (C284H439N94O87S [M+10H]
90+, calcd. 
684.8), 622.1 (C284H438N94O87S [M+11H]
11+, calcd. 622.1). 
 
Removal of Auxiliary from Ligation Product (3.095): done according to general protocol 
method C in 0.1 µmol scale to yield His6-MUC1(1-40)-Dbz-Gly 3.097.  
ESI-MS (positive mode) m/z =  1079.8 (C276H420N94O87Na5 [M+5H]
5+, calcd. 1079.8), 880.8 
(C276H426N94O87 [M+6H]
6+, calcd. 880.9), 755.4 (C276H427N94O87 [M+7H]
7+, calcd. 755.2), 661.3 
(C276H428N94O87 [M+8H]
8+, calcd. 660.9), 587.8 (C276H429N94O87 [M+9H]
9+, calcd. 587.6). 
5.4.3.1 Stability Study: His-Tag peptide binding to Ni-NTA resin 
The resin bound peptide was treated with ligation buffer containing 20 mM TCEP and 10 mM 
MPAA to a concentration of 10 mM and kept at rt. Aliquots from supernatant were taken and 
tested for peptide presence. After 4 days, no peptide could be detected in the supernatant. 
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Figure 5.25: Stability test of Ni-His-Tag binding after 72 hr. 03-60% B in 6 min, 210 nm. 
 
5.4.4 Activation of Latent Thioesters for Sequential Auxiliary-Assisted 
SPCL 
 
Transthioesterification of His5-MUC1(1-20)-SBzl (3.102) to yield His5-MUC1(1-20)-SPh 
(3.105b) or His5-MUC1(1-20)- MESA (3.105c): done according to method B in the general 
protocol. 
  
3.105b His5-MUC1(1-20)-SPh:  
ESI-MS (positive mode) m/z =  889.4 (C116H169N40O31S [M+3H]
3+, calcd. 889.3), 667.5 
(C116H170N40O31S [M+4H]
4+, calcd. 667.2), 533.9 (C116H171N40O31S [M+5H]
5+, calcd. 534.0). 
3.105c His5-MUC1(1-20)-MESA  
ESI-MS (positive mode) m/z =  899.6 (C112H169N40O34S2 [M+3H]
3+, calcd. 900.0), 675.3 
(C112H169N40O34S2 [M+4H]
4+, calcd. 675.2), 540.4 (C112H169N40O34S2 [M+5H]
5+, calcd. 540.0). 
 
Converting His6-MUC1(1-20)-NHNH2 (3.111) to thioester His6-MUC1(1-20)-MPAA 
(3.105a): done according to Method A in the general procedure.  
 
3.105a His6-MUC1(1-20)-MPAA: 
 
ESI-MS (positive mode) m/z =  954.1 (C118H171N40O33S [M+3H]
3+, calcd. 954.4), 715.9 
(C118H172N40O33S [M+4H]
4+, calcd. 716.0), 573.0 (C118H173N40O33S [M+5H]
5+, calcd. 573.0), 
477.7 (C118H174N40O33S [M+6H]
6+, calcd. 477.7). 
 134 
 
5.4.5 Total Chemical Synthesis of MUC1(1-80)-His6  
 
Loading on His-Tag Ni-NTA affinity resin: The Ni-NTA resin (70 µl, 70 mg peptide/ml, 50% 
solution) in 30% ethanol in water is taken, washed with degassed deionized water and 
swelled in a freshly degassed buffer of 6M Gn.HCl, 0.1 M NaH2PO4, 20 mM TCEP pH 
7.2 for 20 min. Peptide Aux-MUC1-His6 3.114 (2 mg, 4715 gr/mol, 0.42 µmol) is 
dissolved in same buffer (80 µl, 5 mM) and added to resin. After 1 hr, UPLC analysis of 
the supernatant showed a complete anchoring of the peptide to the resin.  
 
Ligation of Aux-MUC1(41-80)-His6 3.114 and H-MUC1(1-40)-SBzl 3.112 to give H-MUC1(1-
40)-Aux-MUC1(41-80)-His6 3.115: H-MUC1(1-40)-SBzl 3.112 (2 mg, 3862 g/mol, 0.50 
µmol, 1.2 eq) was dissolved in 40 µl freshly degassed buffer containing 6M Gn.HCl, 0.1 
M NaH2PO4, 20 mM TCEP, 10 mM MPAA pH 7.2.and added to resin. Mixture was 
incubated at 25 °C for 72 hr. Every 24 hr, resin was washed and a new batch of thioester 
H-MUC1(1-40)-SBzl 3.112 (0.8 mg, 0.21 µmol, 0.5 eq) in ligation buffer was added to 
resin. 
Monitoring the ligation: Resin is washed with buffer of 6M Gn.HCl, 0.1 M NaH2PO4, 20 mM 
TCEP pH 7.2 and degassed water. Analytical amount of resin is taken, and treated 
with 20 µl elution buffer containing 250 mM imidazole and 20 mM TCEP in water pH 
8.0 for 20 min. 2 µl are taken and diluted with 18 µl H2O+ 0.1% TFA and injected on 
UPLC-MS. 
Stability Control: To check that the peptide anchoring to the resin is stable to the long exposure of 
TCEP and MPAA an aliquot from the supernatant was taken and injected on UPLC-
MS. The results showed no presence of the auxiliary peptide in the supernatant. Only 
the thioester peptide 3.112 and the thioester MPAA exchange species were detected. 
Elution of ligation product H-MUC1(1-40)-Aux-MUC1(41-80)-His6 3.115 from solid support: 
The resin is thoroughly washed with buffer containing 6M Gn.HCl, 0.1 M NaH2PO4, 
20 mM TCEP pH 7.2, water, H2O+ 0.1% TFA, water. Resin is drained and the 
elution buffer (40 µl) is added for 30 min. The elution buffer is taken and process is 
repeated once more. The resin is then washed with elution buffer (2 X 10 µl) and all 
washes are combined. 
ESI-MS (positive mode) m/z =  1208.3 (C364H560N119O114S [M+7H]
7+, calcd. 1208.5), 1057.2 
(C364H561N119O114S [M+8H]
8+, calcd. 1057.5, 940.5 (C364H562N119O114S [M+9H]
9+, calcd.940.1), 
846.5 (C364H563N119O114S [M+10H]
10+, calcd. 846.2), 769.3 (C364H564N119O114S [M+11H]
11+, calcd. 
769.4), 705.4 (C364H565N119O114S [M+12H]
12+, calcd. 705.4). 
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Removal of Auxiliary from ligation product H-MUC1(1-40)-Aux-MUC1(41-80)-His6 3.115 to 
yield H-MUC1(1-80)-His6 peptide 3.116: To an Eppendorf containing ligation product 4 in the 
elution buffer  
                    (100 µl) is added 100 µl of aqueous buffer containing 400 mM morpholine and 100 
mM   
                    TCEP pH 8.5 and incubated at 25 °C for 24 hr after which a full conversion to 
peptide  
                     3.116 is achieved as observed by UPLC-MS. 
Purification of  H-MUC1(1-80)-His6 3.116: The peptide in the solution above is diluted with 700 
µl H2O+ 0.1% TFA and purified on a semi-preparative HPLC using a gradient of 03-
60% B in 30 min. Combined fractions are united and lyophilized to yield the pure 
MUC1(1-80)-His6 5 as a white solid. 
3.116 H-MUC1(1-80)-His6: 1.5 mg, 8316 gr/mol, 0.19 µmol, 45%.  
ESI-MS (positive mode) m/z =  1189.5 (C356H552N119O114 [M+7H]
7+, calcd. 1189.0), 1040.5 
(C356H553N119O114 [M+8H]
8+, calcd. 1040.5, 925.0 (C356H554N119O114 [M+9H]
9+, calcd.925.0), 
832.6 (C356H555N119O114 [M+10H]
10+, calcd. 832.6), 757.0 (C356H556N119O114 [M+11H]
11+, calcd. 
757.0), 694.0 (C C356H557N119O114 [M+12H]
12+, calcd. 694.0), 640.0 (C356H558N119O114 
[M+13H]13+, calcd. 640.7), 595.0 (C356H559N119O114 [M+14H]
14+, calcd. 595.0). 
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Appendix A: Spectrometry Data 
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A.2 UPLC-MS Analysis 
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Appendix B: List of Abbreviations 
Ac Acetyl 
Ac2O Acetic anhydride 
Acm Acetamidomethyl 
Alloc Allyloxycarbonyl 
AMP Antimicrobial peptide 
Ar Aryl 
Aux Auxiliary 
Bnz Benzyl 
Boc tert-Butoxycarbonyl 
BOP Bis(2-oxo-3-oxazolidinyl)phosphine 
t-Bu or tBu tert-Butyl 
Bzl Benzyl 
cHex Cyclohexane 
CI2 Chymotrypsin Inhibitor 2 
Da Dalton 
Dbz 3,4-Dimethylbenzoic acid 
DCD-1L Dermicidin 
DCM Dichloromethane 
DIC Diisopropylcarbodiimide 
DIPEA Diisopropylethylamine 
DMF N,N-Dimethylformamide 
DMP Dess-Martin periodinane 
DMSO Dimethylsulphoxide 
DPA Diisopropylamine 
EDC 1-Ethyl-3-(3-dimethylaminopropy)carbodiimide 
EDMA Ethyldimethylamine 
Eq Equivalent 
ESI Electrospray ionization 
Et Ethyl 
EtOH Ethanol 
Et2O Diethyl ether 
et al. et alia 
EtOAc Ethyl Acetate 
EWG Electron withdrawing group 
FMOC 9-Fluorenylmethoxycarbonyl 
Gn.HCl Guanidinium hydrochloride 
HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate HBTU 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
HCTU O-(6-Chlorobenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate 
 
HCY Homocysteine 
HPLC High performance liquid chromatography 
HOBt 1-Hydroxybenzotriazole 
hr hour 
KAHA ketoacid-hydroxylamine 
KCL Kinetically controlled ligation 
MBHA 4-methylbenzhydrylamine 
Me Methyl 
MeOH Methanol 
MESA 2-Mercaptoethylsulfonic acid 
MESNa Sodium 2-mercaptoethylsulfonate 
MPA 3-mercaptopropylacetic acid 
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MPAA 4-mercaptophenylacetic acid 
MS Mass spectroscopy 
MUC1 Mucin 1 
Nbz 1H-benzo[d]imidazol-2(3H)-one 
NCL Native chemical ligation 
NMA N-methylaniline 
NMM N-Methylmorpholine 
NMP N-Methylpyrrolidone 
NMR Nucleic magnetic resonance 
NTA Nitriloacetic acid 
OxymaPure  Ethyl (hydroxyimino)cyanoacetate 
Ph Phenyl 
Pip Piperidine 
i-Pr or iPr iso-propilo 
PyBOP benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate 
rt Room temperature 
SAL Sugar assisted ligation 
BzlSH/ SBzl benzylmercpatane 
SCAL Side chain assisted ligation 
SEA bis(2-sulfenyl)amino 
SPCL Solid phase chemical ligation 
SPPS Solid phase peptide synthesis 
PhSH/ SPh Thiophenol/yl 
TCEP tris(2-carboxyethyl)phosphine 
TEA Triethylamine 
TES Triethylsilane 
TFA Triflouroacetic acid 
TFMSA Trifluoromethanesulfonic acid 
THF Tetrahydrofurane 
Thz Thiazolidine 
TIS Triisopropylsilyl 
TL Thiolactone 
Tmob 4,5,6-trimethoxy-2-mercaptobenzyl 
TMOF trimethylorthoformate 
TMS Trimethylsilyl 
tR Retention time 
Trt Trityl, triphenylmethyl 
UPLC Ultra performance liquid chromatography 
UV Ultra violet 
VNTR variable number tandem repeat 
 
